Lipid Controlled Release Compositions

High-purity diacylglycerol compositions in lipid-based formulations stored in silicone-free glass syringes address turbidity and precipitate issues, ensuring clear and stable administration of bioactive agents.

JP7578620B2Active Publication Date: 2024-11-06CAMURUS AB
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2021569162
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-05-29
Filing Date
2020-05-29
Publication Date
2024-11-06
Estimated Expiration
2040-05-29

AI Technical Summary

Technical Problem

Existing lipid-based pharmaceutical formulations suffer from turbidity and precipitate formation when stored under refrigerated conditions and equilibrated at room temperature, which can hinder administration and limit the selection of bioactive agents.

Method used

The use of high-purity diacylglycerol compositions, such as glycerol dioleate, in lipid-based formulations stored in glass syringes without silicone oil, reduces turbidity and precipitate formation by minimizing saturated impurities, ensuring clarity and injectability.

Benefits of technology

The method maintains the formulations as a clear liquid with reduced precipitates, allowing safe and effective administration without the need for pre-applied lubricants, thus enhancing stability and compliance for long-term storage and use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007578620000007
    Figure 0007578620000007
  • Figure 0007578620000008
    Figure 0007578620000008
  • Figure 0007578620000009
    Figure 0007578620000009
Patent Text Reader

Abstract

The present disclosure provides glass syringes or glass cartridges containing lipid-based preformulations suitable for refrigerated storage.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to lipid compositions, particularly those suitable for use in the formulation of pharmaceuticals, and to preformulations comprising such lipid compositions. The present disclosure further relates to the use of certain lipid compositions in preventing or reducing the formation of long-lived precipitates during storage of lipid pharmaceuticals. [Background technology]

[0002] Many bioactive agents, including pharmaceuticals, nutrients, vitamins, etc., have a "functional window." That is, there is a range of concentrations at which these agents can be observed to achieve some biological effect. If the concentration in the appropriate part of the body (e.g., locally or as indicated by serum concentration) falls below a certain level, no beneficial effect can be attributed to the agent. Similarly, there is generally an upper concentration level above which increasing the concentration does not provide any further benefit. In some cases, increasing the concentration above a certain level results in undesirable or dangerous effects.

[0003] Some bioactive agents have a long biological half-life and / or a wide functional window, and therefore, when administered from time to time, can maintain a functional biological concentration for a significant period (e.g., 6 hours to several days). In other cases, the clearance rate is high and / or the functional window is narrow, and therefore small regular (or even continuous) doses are required to maintain the biological concentration within this window. This can be particularly difficult when a parenteral route of administration (e.g., parenteral administration) is desired or necessary, as self-administration can be difficult and therefore leads to inconvenience and / or poor compliance. In such cases, it is advantageous to provide the active agent at therapeutic levels for the entire period that activity is required for a single administration.

[0004] Some patients undergoing treatment typically require that the therapeutic dose be maintained for a significant period of time and / or that the current treatment continue for months or years. Thus, a depot system that allows for the loading and controlled release of larger doses over a longer period of time offers significant advantages over conventional delivery systems.

[0005] Certain formulations of the present disclosure produce non-lamellar liquid crystal phases following administration.The use of non-lamellar phase structures (e.g., liquid crystal phases) in the delivery of bioactive agents is now relatively well established.Highly effective lipid depot systems are described in WO2005 / 117830.However, there is still room to achieve depot formulations with improved performance in some respects.

[0006] In particular, it has been observed that certain lipid-based compositions, such as the lipid depot system described in WO2005 / 117830, may remain cloudy or "cloudy" in appearance when brought to room temperature after having been stored under refrigerated conditions. This turbidity remains even when the preformulation is equilibrated at room temperature. Turbidity is undesirable in injectable pharmaceuticals and may be prohibited for regulatory and / or safety reasons. As used herein, "turbidity" is used to indicate a lack of clarity in a solution. This may be due to suspension, precipitation, separation or other reasons of liquid or solid materials in the solution.

[0007] Turbidity, including opalescence and the formation of precipitates in a pharmaceutical agent that take a long time to redissolve or remain insoluble, can mean that the pharmaceutical agent is more difficult to administer to a subject, or in many cases, prevents such administration. Because some active agents must be stored under refrigerated conditions to prevent degradation of the active agent, the formation of these long-lived precipitates and / or turbidity can actually limit the selection of active agents that can be administered as part of such lipid-based formulations. [Prior art documents] [Patent documents]

[0008] [Patent Document 1] International Publication No. 2005 / 117830 Summary of the Invention [Problem to be solved by the invention]

[0009] Thus, there is a need to provide a method for preparing lipid-based formulations that can be stored under refrigerated conditions and safely administered to a subject without turbidity, opalescence and / or precipitate.

[0010] The inventors have now established that by preparing a formulation using a high-purity diacylglycerol composition (at manufacturing scale) in combination with a specific glass syringe that has an inner surface that is in contact with the lipid-based formulation and is free of silicone oil or even pre-applied lubricant, it is possible to provide a lipid-based formulation with reduced turbidity and / or precipitate formation after refrigerated conditions.By preparing a lipid-based formulation that includes a high-purity diacylglycerol composition, for example, glycerol dioleate, and filling it into a glass syringe that is free of silicone oil, the formation of precipitate and opalescence / turbidity after storage under refrigerated conditions and subsequent equilibration at room temperature is surprisingly reduced while maintaining injectability. [Means for solving the problem]

[0011] In a first aspect, the present disclosure provides a glass syringe or glass cartridge containing a lipid-based pre-formulation, wherein at least an interior surface of the glass syringe or glass cartridge is in contact with the lipid-based pre-formulation, said interior surface being free of a pre-applied silicone lubricant, and the lipid-based pre-formulation comprises: a) 20-80% by weight of diacylglycerol having a fatty acid composition of at least 98% oleic acid (18:1) as determined according to European Pharmacopoeia 9.0, Method C, 2.4.22 (Composition of fatty acids by gas chromatography); b) 20-80% by weight of phospholipids; c) 1-30% by weight of a solvent; d) Bioactive Agents wherein a) and b) are at least 94% by weight of the total lipid content of the lipid-based pre-formulation, and the lipid-based pre-formulation has a lipid content of at least 94% by weight of the total lipid content of the lipid-based pre-formulation, and has a lipid content of at least 94% by weight of the total lipid content of the lipid-based pre-formulation, after storage at a temperature of 10° C. or less, e.g., between 0° C. and 10° C., e.g., between 2° C. and 8° C. for at least one month, followed by equilibration at room temperature for a period of at least one hour, as measured by USP <790> The composition is a clear liquid having a viscosity of less than 1000 mPas at 20° C. as determined in accordance with the method of the present invention and is essentially free of visible precipitate.

[0012] In one embodiment, the glass syringe or glass cartridge contains a lipid-based preformulation, the preformulation comprising a lipid-based formulation according to USP <788> The present invention relates to a method for preparing a turbidity-reducing emulsion comprising the steps of: (a) detecting a particle size distribution of a turbidity-reducing emulsion comprising: (i) detecting a particle size distribution of a turbidity-reducing emulsion comprising:

[0013] Viewed from a second aspect, the present disclosure provides a method of administering a lipid-based pre-formulation compressed into a glass syringe or glass cartridge according to the appended claims and embodiments and aspects described herein to a patient in need thereof, wherein the glass syringe or glass cartridge containing the pre-formulation is maintained at a temperature of 10° C. or below, e.g., 0° C. to 10° C., e.g., 2° C. to 8° C. prior to administration and is equilibrated to room temperature prior to administration.

[0014] Viewed from a third aspect, the present disclosure provides the use of a diacylglycerol composition having a fatty acid composition of at least 98% oleic acid (18:1), as determined according to European Pharmacopoeia 9.0, Method C, 2.4.22 (Composition of fatty acids by gas chromatography), in preventing or reducing the formation of long-lived precipitates in a pre-formulation comprising said diacylglycerol composition and at least one biocompatible organic solvent.

[0015] Viewed from a fourth aspect, the present disclosure provides a method for producing a semiconductor device comprising: When the pre-formulation is stored at a temperature between 0° C. and 10° C., for example between 2° C. and 8° C., for a period of at least 24 hours, for example at least 1 month, for example at least 3 months, for example at least 6 months, (i) a diacylglycerol composition; and (ii) at least one biocompatible organic solvent; The present invention provides a method for preventing or reducing the formation of long-lived precipitates in the pre-formulation, the method comprising forming the pre-formulation with a diacylglycerol composition according to the first aspect. When the pre-formulation is stored at a temperature between 0° C. and 10° C., for example between 2° C. and 8° C., for a period of at least 24 hours, for example at least 1 month, for example at least 3 months, for example at least 6 months, a) (i) 20 to 80% by weight of diacylglycerol having a fatty acid composition of at least 98% oleic acid (18:1) as determined according to European Pharmacopoeia 9.0, Method C, 2.4.22 (Composition of fatty acids by gas chromatography); b) 20-80% by weight of phospholipids; c) 1-30% by weight of a solvent; d) Bioactive Agents A method for preventing or reducing the formation of long-lived precipitates in lipid-based preformulations comprising:

[0016] Viewed from the fifth aspect, the present disclosure provides a pre-filled glass syringe or glass cartridge according to the first aspect, comprising a barrel having an internal surface pre-filled with lipid-based composition, wherein the part of the internal surface of the barrel that always contacts with lipid-based composition is substantially free of pre-applied lubricant (i.e., free of silicone oil and any other pre-applied lubricant), and by substantially free of pre-applied lubricant, it is understood that no lubricant is added during or after the manufacture of the syringe, i.e., before filling the syringe with lipid-based composition disclosed herein, the internal surface is essentially free of lubricant, for example silicone oil.Examples of suitable syringes, for example, those marketed by Gerresheimer, Schott and BD (Becton, Dickinson and Company), for example, 1mL glass syringes are commercially available, but the internal surface is free of silicone oil or free of lubricant.

[0017] In a further aspect, the present disclosure provides a method of administering a pre-formulation according to the present disclosure contained in a syringe without silicone oil to a patient in need thereof, wherein the syringe containing the pre-formulation is maintained at a refrigerated temperature (e.g., 2-8° C.) for up to about 1 hour prior to administration (e.g., up to 24 months prior to administration) and equilibrated at room temperature (15-25° C., e.g., at 25 C) for about 1 hour prior to administration.

[0018] The preformulation should be, for example, a clear liquid that does not exhibit visible haze (turbidity) upon administration. Turbidity is determined according to the USP <790> According to the above, it can be detected by visual inspection.

[0019] In a further aspect, the present disclosure provides a syringe according to the first aspect, wherein the stability of the pre-formulation is at least 6 months, such as at least 12 months, such as at least 18 months, when stored at 2-8°C.

[0020] In a further aspect, the present disclosure provides a syringe according to the first aspect, wherein the syringe is provided with a stopper. Examples are commercially available stoppers from BD or West suitable for syringes described herein, e.g., 1 mL glass syringes.

[0021] Further aspects and embodiments are provided in the accompanying claims. [Brief description of the drawings]

[0022] [Figure 1] Photographs of pre-filled syringes according to the present disclosure stored at 5° C. for 14 months taken in polarized light at 0, 5, 15, and 30 minutes after removal from the climate chamber. [Figure 2a] 1 shows a graph of gliding force versus injection time for formulations of various viscosities injected through a 22G TWW needle. [Figure 2b] 1 shows a graph of gliding force versus injection time for formulations of various viscosities injected through a 23G UTW needle. [Diagram 3] The correlation between the estimated sliding and breakaway forces is shown. [Figure 4] Photograph of a pre-filled glass syringe according to Example 2. [Diagram 5] Photograph of a pre-filled glass syringe according to Example 2. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0023] The present disclosure provides a high purity diacylglycerol composition. As used herein, the term "high purity diacylglycerol composition" is understood to be a composition or formulation containing at least 97.0% by weight of diacylglycerol having two fatty acid residues each having 16-20 carbon atoms and one or two carbon-carbon double bonds, e.g., a fatty acid composition of at least 98% oleic acid (18:1) as determined according to European Pharmacopoeia 9.0, method C, 2.4.22 (composition of fatty acids by gas chromatography).

[0024] All percentages are specified by weight throughout this specification unless otherwise indicated. Weight percentage (%) can be abbreviated to, for example, wt%. Furthermore, the weight percentages indicated are % of the total composition or formulation, including all of the components indicated herein, unless otherwise indicated. When weight percentages are indicated for salts of active agent compounds, the weight percentages refer to the amount (or equivalent) of free base, unless otherwise indicated. In certain instances, the weight percentages of specific salts are provided, but are indicated where appropriate and can be easily converted to the corresponding weight of free base.

[0025] When a composition or formulation is described herein as "consisting essentially of" a particular component, for example, when the particular component constitutes at least 95% of the formulation, preferably at least 98%, the particular component provides the essential properties of the formulation. This applies equally to any component or composition that may be formed from multiple materials. Similarly, when the use of "about," "approximately," "approximately," or similar language is present herein, this indicates that the particular amount is the primary embodiment, but the actual amount should not be substantially different from the specified amount as determined by one of ordinary skill in the art. This is typically ±10%, ±5%, or ±1% of the particular value, unless the context prohibits.

[0026] Herein, particularly in relation to the claims, the language "comprising or consisting of" an agent or component "selected from the group consisting of" is used to indicate two embodiments; an open group for the "comprising" embodiment, and a closed group for the "consisting of" embodiment. In the latter case, the list of agents and components may be considered closed and terminated at the last instance of the "and" list. This language may therefore be interpreted as "selected from the group consisting of ... and ...".

[0027] Whenever the terms "comprising" or "containing" are used in aspects, embodiments, claims, etc. in this disclosure, such terms are understood to encompass those aspects, embodiments, and claims in which said terms are replaced with "consisting essentially of" or "consisting of." A specific example is that whenever the term "glass syringe or glass cartridge containing a lipid-based pre-formulation" is used, it is believed that the following "glass syringe or glass cartridge consisting essentially of a lipid-based pre-formulation" and "glass syringe or glass cartridge consisting of a lipid-based pre-formulation" are clearly intended.

[0028] When any active agent (e.g., drug or API) is disclosed herein, this is also a disclosure of the active agent in the form of any pharma- ceutically acceptable salt, unless the context prohibits. Suitable pharmaceutical salts are well known in the art, and suitable examples for all embodiments are described herein. Salts such as halides (especially chlorides), acetates, pamoates, etc. are examples of suitable salts of basic moieties. Alkali metal, alkaline earth metal, amine or alkylamine salts are examples of suitable salts of acid moieties.

[0029] The term "precursor formulation" or pre-formulation is used herein to denote a pharmaceutical formulation that can be injected to yield a controlled release "depot" formulation within the body of a subject. A pre-formulation can consist essentially of, and in one aspect consist entirely of, the components optionally set forth herein (including appropriate further optional components set forth herein below and in the appended claims).

[0030] In one embodiment, the diacylglycerol composition of any suitable aspect comprises at least 97.5% by weight, e.g., at least 98.0% by weight, e.g., at least 98.5% by weight, of diacylglycerol having two fatty acid residues each independently having 16-20 carbon atoms and 1 or 2 carbon-carbon double bonds. In one embodiment, the diacylglycerol composition consists essentially of diacylglycerol having two fatty acid residues each independently having 16-20 carbon atoms and 1 or 2 carbon-carbon double bonds, e.g., glycerol dioleate having a fatty acid composition of at least 98% oleic acid (18:1) as determined according to European Pharmacopoeia 9.0, Method C, 2.4.22 (Composition of fatty acids by gas chromatography).

[0031] While diacylglycerol compositions are known in the art, diacylglycerol compositions having purity as high as the diacylglycerol compositions of the present disclosure have not been previously used in the manufacture of pharmaceutical products, such as lipid-based preformulations, such as those described herein, and are used in combination with glass syringes or glass cartridges without pre-applied silicone lubricant (e.g., silicone oil).

[0032] The inventors have surprisingly established that when lipid-based formulations are produced using the high purity diacylglycerol compositions of the present disclosure instead of the conventional (less pure) diacylglycerol compositions known in the prior art, the turbidity observed after thawing the lipid-based composition after storage under refrigerated conditions is reduced or eliminated (see, e.g., USP <790> (As determined by visual inspection by ). The present inventors have also established a method by which high purity diacylglycerol can be synthesized.

[0033] Without being bound by theory, it is believed that the presence of saturated impurities in lipid-based compositions is responsible for the turbidity observed when formulations incorporating the compositions are stored under refrigerated conditions and subsequently equilibrated at room temperature.By preparing a formulation having a diacylglycerol composition with high purity, the amount of saturated impurities in the formulation can be reduced, and therefore the amount of insoluble long-lived precipitate formed by refrigerated storage and subsequent thawing is also reduced.

[0034] In one embodiment, the diacylglycerol composition thus comprises less than 3% by weight of saturated fatty acid residues. In one embodiment, the diacylglycerol composition comprises less than 2% by weight, for example, less than 1% by weight of saturated fatty acid residues. The amount of saturated fatty acid residues in the diacylglycerol composition can be measured by any means known in the art, for example, by gas chromatography (GC). A particularly suitable method can be found in the European Pharmacopoeia 9.0, method C, 2.4.22 (composition of fatty acids by gas chromatography).

[0035] Desirably, the fatty acid residues of the diacylglycerol each independently have 16-20 carbon atoms. In one embodiment, the fatty acid residues of the diacylglycerol each independently have 16-20 carbon atoms. In one embodiment, the fatty acid residues each independently have 16 or 18 carbon atoms. In one embodiment, the fatty acid residues each independently have 16 carbon atoms or 18 carbon atoms. In one embodiment, the fatty acid residues each have 18 carbon atoms.

[0036] Desirable fatty acid residues of the diacylglycerol each independently have one or two carbon-carbon double bonds. In one embodiment, the fatty acid residues of the diacylglycerol each have one carbon-carbon double bond or each have two carbon-carbon double bonds. In one embodiment, the fatty acid residues each have one carbon-carbon double bond.

[0037] In one embodiment, the fatty acid residues of the diacylglycerol are independently oleic acid residues (C18:1) or linoleic acid residues (C18:2). The designation "CX:Z" denotes a hydrocarbon chain having X carbon atoms and Z unsaturations (particularly double bonds). In one embodiment, the fatty acid residues are respectively oleic acid residues or respectively linoleic acid residues. In one embodiment, the fatty acid residues are respectively oleic acid residues, i.e., the diacylglycerol is glycerol dioleate. It is an important embodiment that in all aspects herein, the diacylglycerol referred to herein may be glycerol dioleate, glycerol dilinoleate or a mixture thereof. In one embodiment, the diacylglycerol referred to herein in all aspects may be glycerol dioleate.

[0038] In one embodiment, the diacylglycerol having two fatty acid residues, each having 16-20 carbon atoms and one or two carbon-carbon double bonds, is a mixture of 1,2-diacylglycerol and 1,3-diacylglycerol isomers. In one embodiment, the isomeric ratio of 1,2-diacylglycerol to 1,3-diacylglycerol is 5:1 to 1:5, such as 4:1 to 1:4, for example, 1:1.5 to 1:3.5 (e.g., 1:2 to 1:3).

[0039] In one embodiment, the diacylglycerol composition comprises 2% by weight or less, such as 1.5% by weight or less, such as 1% by weight or less, such as 0.5% by weight or less, of monoacylglycerol. In one embodiment, the diacylglycerol composition comprises 2.5% by weight or less, such as 2% by weight or less, such as 1.5% by weight or less, of triacylglycerol.

[0040] Preliminary Formulation In one aspect, the present disclosure relates to a precursor formulation (also referred to as a "preformulation") comprising: i) a diacylglycerol composition having a fatty acid composition of at least 98% oleic acid (18:1) as determined according to European Pharmacopoeia 9.0, Method C, 2.4.22 (Composition of Fatty Acids by Gas Chromatography); and ii) at least one biocompatible organic solvent. Component i) of the diacylglycerol composition can be a diacylglycerol composition described herein.

[0041] As used herein, the term "formulation" or "preformulation" refers to a mixture of components (i) and (ii) and, optionally, other components. A preformulation is typically of low viscosity. The term "preformulation" indicates that the formulation forms or is capable of forming at least one non-lamellar (especially liquid crystalline) phase structure upon contact with an excess of aqueous liquid.

[0042] The term "depot" refers to a composition formed by exposure of a preformulation to excess aqueous liquid, for example during parenteral administration. Without being bound by theory, it is believed that this change is at least partially brought about by the exchange of solvent (ii) for aqueous liquid and / or by the addition of aqueous liquid to the lipid structure. Depots typically have a much higher viscosity than the corresponding preformulations, providing for a gradual release of the active agent contained within the depot.

[0043] In one embodiment, the preformulations of the present disclosure result in a non-lamellar phase (e.g., a non-lamellar liquid crystalline phase) following administration. The use of non-lamellar phase structures (e.g., liquid crystalline phases) in the delivery of bioactive agents is now relatively well established. Effective lipid depot systems are described in WO 2005 / 117830, which is incorporated herein by reference. Attention is directed to the discussion in WO 2005 / 117830, in particular page 29, for a description of the most convenient phase structures of such formulations. Preferably, the preformulations according to the present disclosure are dissolved in a molecular solution or liquid crystal phase prior to administration. 2 It has a phase structure.

[0044] The pre-formulations of the present disclosure form or are capable of forming at least one liquid crystalline phase structure upon contact with an excess of aqueous liquid, where "excess aqueous liquid" is understood herein to be a volume of aqueous liquid at least 10 times (e.g., 10-1000 times) greater than the volume of the pre-formulation.

[0045] In one embodiment, which is applicable to all aspects of the present disclosure, the preformulation according to the present disclosure is a molecular solution or L 2 The preformulation has a phase structure (before administration). The preformulation forms a non-lamellar (e.g., liquid crystal) phase following administration. Such a phase change is typically brought about by absorption of aqueous liquid from the physiological environment as shown herein. It has previously been established in WO 2012 / 160213 that a carefully controlled amount of water can be tolerated (although monoalcoholic solvents are present), but it is understood that upon administration, the preformulation is exposed in vivo to a large amount of aqueous liquid, which leads to the formation of a non-lamellar phase. Typically, the preformulation forms a non-lamellar phase upon contact with at least an equal volume of aqueous liquid.

[0046] The viscosity of the preformulations of the present disclosure can be controlled by their formulation, but is typically within a range that can be effectively delivered by a syringe or autoinjector within an acceptable period of time (e.g., less than 30 seconds). Suitable viscosities can be 10-1000 mPas at 25° C., for example, 100-800 mPas or 200-600 mPas at 25° C. A viscosity of 300-500 mPas at 25° C. can be suitable.

[0047] Component (i): Diacylglycerol composition The preformulation of the present disclosure comprises a diacylglycerol composition having a fatty acid composition of at least 98% oleic acid (18:1) as determined according to European Pharmacopoeia 9.0, Method C, 2.4.22 (Composition of Fatty Acids by Gas Chromatography). In one embodiment, this diacylglycerol composition is the only diacylglycerol present in the preformulation, i.e., the preformulation is substantially free of diacylglycerol other than the diacylglycerol composition having a fatty acid composition of at least 98% oleic acid (18:1) as determined according to European Pharmacopoeia 9.0, Method C, 2.4.22 (Composition of Fatty Acids by Gas Chromatography).

[0048] The principle difference between the preformulation of the present disclosure and those known in the prior art is that the preformulation of the present disclosure comprises a high purity diacylglycerol composition as defined herein. The inventors have surprisingly established that when the preformulation is prepared using the high purity diacylglycerol composition of the present disclosure, optionally in combination with a syringe having an inner surface without pre-applied lubricant, the formation of long-lived precipitates in the composition after storage under refrigerated conditions, e.g., 2-8°C, can be reduced and prevented, for example, by storage for one month or longer.

[0049] Without wishing to be bound by theory, it is believed that the formation of long-lived precipitates in prior art formulations after storage under refrigerated conditions is due to the presence of saturated impurities in the lipid component. The use of the high purity diacylglycerol compositions of the present disclosure reduces the level of saturated impurities in the formulation, thus preventing or reducing the formation of said long-lived precipitates.

[0050] Component (ii): Biocompatible organic solvent Component (ii) of the pre-formulation of the present disclosure is at least one biocompatible organic solvent. Component (ii) can be a single solvent or a mixture of two or more solvents. Because the pre-formulation will or can form a depot composition following administration (e.g., in vivo), it is desirable that these solvents are acceptable to the subject and can mix with and / or diffuse or dissolve from the pre-formulation into the aqueous liquid upon contact with excess aqueous liquid. Solvents with at least moderate water solubility are therefore preferred. As described herein below, component ii) can include a polar co-solvent, such as propylene glycol.

[0051] As used herein, the term "biocompatible organic solvent" is understood to be a solvent that is safe for use in mammalian subjects (e.g., humans).Typically, biocompatible organic solvents have an LD50 (as calculated by oral administration in rats) of more than 700 mg / kg, for example more than 1000 mg / kg, particularly more than 1500 mg / kg.LD50 data for commonly used solvents is readily available in MSDS sheets.

[0052] In one embodiment, component ii) comprises or consists of at least one solvent selected from the group consisting of alcohols, amines, amides and esters. Preferably, component ii) comprises at least one monoalcoholic solvent. Most preferably, component ii) comprises ethanol, propanol, isopropanol, or a mixture thereof. It is particularly preferred that component ii) comprises or consists of ethanol. Component ii) may comprise or consist of a monoalcoholic solvent, preferably ethanol, and a polar cosolvent. A mixture comprising or consisting of ethanol and propylene glycol is suitable. In an embodiment, the biocompatible organic solvent is a biocompatible oxygen-containing organic solvent.

[0053] Examples of solvents are ethanol, propylene glycol (PG), water for injection (WFI), benzyl alcohol, dimethyl sulfoxide (DMSO), and N-methyl-2-pyrrolidone (NMP) and mixtures thereof. In some embodiments disclosed herein, the solvent is ethanol, propylene glycol (PG), dimethyl sulfoxide (DMSO), and N-methyl-2-pyrrolidone (NMP) and mixtures thereof.

[0054] Component (ii) may comprise two or more components from the list of solvents above, in particular a solvent selected from a monoalcoholic solvent, and an amide, sulfoxide or dialcoholic solvent. Any solvent that is not a monoalcoholic solvent may be referred to herein as a co-solvent. When two or more solvents are present, suitable combinations include ethanol and an amide (e.g., ethanol and N-methylpyrrolidone (NMP)), ethanol and a sulfoxide (e.g., ethanol and dimethylsulfoxide (DMSO)), or ethanol and a dialcoholic or polyalcoholic solvent (e.g., ethanol and propylene glycol (PG)). Ethanol and PG form an embodiment.

[0055] A suitable combination of solvents is ethanol and PG, in particular the ratio of ethanol to PG is 1:5 to 20:1, such as 1:1 to 10:1, such as 1.5:1 to 8:1, such as 2:1 to 5:1 (such as approximately 3:1, such as 2.8:1 to 3.2:1). In one embodiment, component (ii) may be a biocompatible oxygen-containing solvent, such as a solvent selected from the group consisting of ethanol, NMP, propylene glycol, benzyl alcohol, DMSO, dimethylformamide, dimethylacetamide and mixtures thereof. Component (ii) may comprise or consist of ethanol, or may comprise or consist essentially of a mixture of ethanol and PG. In one embodiment, component (ii) comprises or consists essentially of propylene glycol.

[0056] The amount of component (ii) in the preformulation has a significant effect on several features. In particular, viscosity and rate (and duration) of release vary considerably with the solvent level. The amount of solvent is thus at least sufficient to achieve a low viscosity mixture, but is also determined to achieve the desired release rate. This can be routinely determined in light of the examples below. Typically, a level of solvent of 1-30%, especially 2-25%, achieves suitable release and viscosity characteristics. This is preferably 2-20%, preferably 5-15%, with amounts of around 10% (e.g. 10±3%) being highly effective. These levels include any co-solvent present as part of component (ii) as described above.

[0057] As noted above, the amount of component (ii) in the preformulations of the present disclosure is at least sufficient to achieve a low viscosity mixture (e.g., a molecular solution) of components (i) and (ii), and is readily determined for any particular combination of components by standard methods.

[0058] The phase behavior of any preformulation, composition, or mixture may be analyzed by techniques such as visual observation in combination with polarized light microscopy, X-ray scattering and diffraction techniques, nuclear magnetic resonance, and cryo-transmission electron microscopy (cryo-TEM) to determine the phase behavior of solutions, L 2 Or L 3 One may look for a phase, or a liquid crystal phase, or dispersed fragments of such phases, as in the case of cryo-TEM. Viscosity may be measured directly by standard means. As described herein, a suitable practical viscosity is one that can be effectively poured and, in particular, sterile filtered. This is easily assessed as shown herein.

[0059] It is preferred that little or no component ii) contains halogen-substituted hydrocarbons, as these tend to have lower biocompatibility.

[0060] Component (ii), as used herein, can be a single solvent or a mixture of suitable solvents, but generally has low viscosity.This is important because one of the important aspects of the present disclosure is to provide a preformulation that has low viscosity, and the main role of suitable solvent is to reduce this viscosity.This reduction is a combination of the effect of the lower viscosity of the solvent and the effect of the molecular interaction between the solvent and lipid composition.One of the inventors' observations is that the low-viscosity oxygen-containing solvent described herein has highly favorable and unexpected molecular interaction with the lipid portion of the composition, thereby realizing a non-linear reduction in viscosity with the addition of a small volume of solvent.

[0061] The viscosity of the "low viscosity" solvent component (ii) (single solvent or mixture) should typically be no more than 18 mPas at 20° C. It is preferably no more than 15 mPas, more preferably no more than 10 mPas, and most preferably no more than 7 mPas at 20° C.

[0062] In WO 2012 / 160213, it is described that the addition of a polar solvent in addition to a monoalcohol solvent provides a number of advantages, including reduced viscosity and reduced active agent burst profile. In addition to the preferred aspects previously described for component ii), in one particularly preferred embodiment, component ii) comprises a monoalcohol solvent and a polar co-solvent. The term "polar co-solvent" as used herein defines a solvent having a dielectric constant (diel) of at least 28 at 25°C, more preferably at least 30 at 25°C, but is not water or any aqueous liquid. Highly suitable examples include propylene glycol (diel about 32) and N-methyl-2-pyrrolidone (NMP, diel about 32). The preferred levels of component ii) listed herein apply equally to mixtures of monoalcohol solvents and polar co-solvents, unless the context otherwise permits.

[0063] Typical cosolvents have a relatively high dielectric constant corresponding to their high polarity. Thus, suitable cosolvents generally have a dielectric constant of at least 28 at 25° C., more preferably at least 30 at 25° C. Highly suitable examples include water (about 80), propylene glycol (about 32), dimethyl sulfoxide (about 47), and N-methyl-2-pyrrolidone (NMP, about 32). Propylene glycol is particularly useful in conjunction with some active agents.

[0064] In a particularly preferred embodiment, component ii) comprises, consists essentially of, or consists of a mixture of a monoalcoholic solvent and a polar co-solvent. The polar co-solvent may in one embodiment be a dialcoholic C3-C6 organic solvent, i.e. a C3-C6 organic solvent containing two hydroxy groups. The dialcoholic solvent is preferably propylene glycol. When present, the polar co-solvent is included at a level of 2-12%, for example 3-10%, especially 4-9% by weight of the pre-formulation. This level counts as part of the ranges recited above for component ii). Most preferably, component ii) comprises, consists essentially of, or consists of a mixture of ethanol and propylene glycol (PG).

[0065] When both an organic monoalcohol solvent and a polar co-solvent, such as ethanol and PG, are present, the ratio of monoalcohol solvent to polar co-solvent is preferably within the range of 20:80 to 70:30, preferably 30:70 to 70:30 (w / w), more preferably 40:60 to 60:40. Approximately equal amounts of mono- and di-alcohol components are highly suitable.

[0066] In a particularly preferred embodiment, component ii) is present at a level of 1-30% and comprises, consists of or consists essentially of a mixture of ethanol and PG, where the ratio (w / w) of ethanol to PG is in the range of 30:70 to 70:30, preferably 40:60 to 60:40. More preferably, component ii) is present in the range of 5-15% or 8-18% by weight, most preferably 8-18% by weight, and is a mixture of ethanol and PG in a ratio (w / w) of 40:60 to 60:40.

[0067] For the avoidance of doubt, even when polar co-solvents are present in the pre-formulations of the present disclosure, the total water levels remain as described in various embodiments herein (e.g., 0.1-1.0 wt %).

[0068] In some embodiments, particularly suitable combinations of solvents for component (ii) include a monoalcohol solvent and a co-solvent selected from the group consisting of amides, sulfoxides or diols. Particularly preferred combinations are ethanol and amides, ethanol and sulfoxides or ethanol and diols. Particularly preferred combinations are ethanol and propylene glycol (PG); ethanol and dimethyl sulfoxide (DMSO); and ethanol and N-methyl-pyrrolidone (NMP).

[0069] When present, a suitable amount of co-solvent is typically more than 1% by weight of the preformulation, for example 2-15% by weight, particularly 4-12% by weight, especially 4-10% by weight. The combination of mono-alcoholic solvent and co-solvent as component (ii) has potential advantages in the compositions of the present disclosure. In particular, the inclusion of some co-solvent that is miscible with the mono-alcoholic component can substantially eliminate any slight sensation that may result at the injection site from the alcoholic content. Thus, in one embodiment, the ratio of mono-alcoholic component:co-solvent can range from 30:70 to 90:10, more preferably 50:50 to 80:20, especially 60:40 to 80:20. Approximately equal amounts of components (w / w) are highly suitable.

[0070] Optional Phospholipid Component In one embodiment, the pre-formulations of the present disclosure include a phospholipid component.

[0071] In embodiments, the phospholipid component is present in an amount of 15-50% by weight of the pre-formulation. In some embodiments, the amount of phospholipid may be 15-45% by weight, for example, 20-45% by weight.

[0072] In an embodiment, the ratio of diacylglycerol composition:phospholipid is 35:65 to 65:35 (w / w), such as 40:60 to 60:40, such as 45:55 to 55:45. A ratio of approximately 50:50 (eg, ±2) is particularly suitable.

[0073] Phospholipids comprise a polar head group and at least one non-polar tail group. In one embodiment, the phospholipid (e.g., phosphatidylcholine (PC)) contains two non-polar groups. In particular, C12-C20, e.g., C16-C18 acyl groups, in each case having zero, one or two unsaturations (e.g., one or two unsaturations), are highly suitable as moieties forming the non-polar group of the phospholipid. In an embodiment, at least 50% of the non-polar groups are oleoyl groups (C18:1).

[0074] In one embodiment, at least 50%, e.g., at least 75% or at least 90% of the non-polar groups of the phospholipid are C16-C18 (e.g., C18:1) moieties, in one embodiment, approximately 100% of the non-polar groups of the phospholipid are such moieties.

[0075] In further embodiments, at least 50%, such as at least 75% or at least 90% of the non-polar groups of the phospholipid are C18 (e.g., C18:1) moieties. In one embodiment, approximately 100% of the non-polar groups of the phospholipid are such moieties.

[0076] In embodiments, the phospholipid comprises or consists of a phospholipid that does not form a non-lamellar liquid crystalline phase structure as a pure compound in water at 25° C. In embodiments, the phospholipid comprises or consists of a phospholipid that forms a non-lamellar liquid crystalline phase structure, e.g., a hexagonal liquid crystalline phase structure, in water at 25° C.

[0077] The phospholipid portion can be derived from natural sources. Suitable sources of phospholipids include egg, (e.g., bovine) heart, brain, (e.g., bovine) liver, and plant sources including soybean. Such sources can provide one or more components of the phospholipid component, which can include any mixture of phospholipids.

[0078] Suitable polar head groups for phospholipids include phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine and phosphatidylinositol. In one embodiment, the preformulation comprises a phospholipid selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), and mixtures thereof. It has been shown in WO2013 / 038460 and WO2013 / 083459 that the use of at least 50% by weight of PE of the total amount of phospholipid can result in improved depot robustness.

[0079] In an embodiment, the phospholipid comprises or consists of one or more PCs. For example, at least 50% of the head groups of the phospholipid should be PC, for example, more than 65% of the head groups, particularly more than 85% or more than 90%. PC from a single source (e.g., soybean PC) or a mixture of PC from different sources (e.g., soybean PC and egg PC) may be used. In an embodiment, the PC component contains at least 50% soybean PC, for example, at least 75% soybean PC, or essentially pure soybean PC. In an embodiment, the PC component contains at least 50% egg PC, for example, at least 75% egg PC, or essentially pure egg PC.

[0080] In one embodiment applicable to all aspects of the present disclosure, the phospholipid comprises or consists of PC, e.g., PC derived from soybeans (soybean PC). PC is available from a variety of suppliers, including Lipoid. Naturally derived PC generally comprises 18:2 fatty acids as the major fatty acid component, with 16:0 and / or 18:1 as secondary fatty acid components. In an embodiment, the ratio between (18:2 fatty acids:other fatty acids) is 1.5:1 and 6:1. PC with approximately 60-65% 18:2, 10-20% 16:0, and 5-15% 18:1 (with the remainder being mainly other 16- and 18-carbon fatty acids) is particularly suitable and typical of soybean PC.

[0081] In an alternative but equally suitable embodiment, also applicable to all aspects of the present disclosure, the PC component may comprise synthetic dioleoyl PC (DOPC). This is believed to provide increased stability and is particularly suitable for compositions that are required to be stable to long-term storage and / or have a long release period in vivo. In this embodiment, the PC component contains at least 50% synthetic dioleoyl PC, e.g., at least 75% synthetic dioleoyl PC, and may be essentially pure synthetic dioleoyl PC.

[0082] In one embodiment, the preformulations of the disclosure are comprised at least in part of synthetic DOPC (i.e., PC having at least 95% PC head groups and at least 90% oleoyl (C18:1) acyl groups) and are stable (defined as less than 5% active agent degradation) upon storage at 15-25° C. after at least 6 months, e.g., at least 12 months or at least 24 months, as assayed by HPLC.

[0083] Because the preformulations of the present disclosure are administered to a subject, it is important that the components are biocompatible. In this regard, both PC and DAG are well tolerated and degrade in vivo into components that occur naturally in the mammalian body.

[0084] Synthetic or highly purified PC, such as dioleoylphosphatidylcholine (DOPC) and palmitoyloleoylphosphatidylcholine (POPC), as well as various other high purity PCs described herein, are highly suitable as all or part of the phospholipid. As used herein, the term "highly purified" refers to PC derived from natural sources that have been subjected to purification to remove contaminants. As used herein, the term "synthetic or highly purified" PC refers to a material that contains at least 95% by weight phosphatidylcholine, where two acyl chains in the PC each independently have 16-20 carbons, and at least one acyl chain has at least one unsaturation in the carbon chain and no more than four unsaturations on the two carbon chains.

[0085] Typically this will be a phospholipid in which at least 95% of the phospholipids have a PC head group and at least 95% of the C16-C20 acyl chains have 0-3 unsaturations.

[0086] In an embodiment, the synthetic PC is DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine). In other embodiments, the synthetic PC is DDPC (1,2-didecanoyl-sn-glycero-3-phosphocholine); DEPC (1,2-dierucoyl-sn-glycero-3-phosphocholine); DLOPC (1,2-dilinoleoyl-sn-glycero-3-phosphocholine); DLPC (1,2-dilauroyl-sn-glycero-3-phosphocholine); DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine); DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine); DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine); DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine); MPPC (1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine); choline); MSPC (1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine); PMPC (1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine); POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine); PSPC (1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine); SMPC (1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine); SOPC (1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine); and SPPC (1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine), or any combination thereof. In all cases, the synthetic PC preferably contains no more than 5% (eg, 0.01-5%) of other materials, such as no more than 2% or no more than 1%.

[0087] Activator The preformulations of the present disclosure include an active agent, also referred to as a bioactive agent. The preformulations of the present disclosure optionally include one or more peptide or non-peptide active agents. It is important to note that the present disclosure is generally applicable, and thus it is recognized that the present disclosure is applicable to preformulations that contain any bioactive agent of interest, particularly active agents that require refrigerated storage, or even that do not contain any bioactive agent at all. The bioactive agent can be any compound that has a desired biological or physiological effect, such as a peptide, protein, drug, antigen, nutrient, cosmetic, fragrance, flavoring, diagnostic agent, pharmaceutical, vitamin, or nutritional agent, and is formulated at a level sufficient to achieve a functional level of in vivo concentration (including local concentration for topical compositions). Suitable active agents include pharmaceuticals, including drugs, vaccines, and diagnostic agents. In certain embodiments, one class of suitable active agents is somatostatin and somatostatin analogs, examples of which are selected from the group consisting of SST-14, SST-28, octreotide, lanreotide, pasireotide, and vapreotide, or salts thereof. In some aspects of the present disclosure, the bioactive agent is octreotide. In some aspects of the present disclosure, the bioactive agent is SST-14.

[0088] In one embodiment, the active agent is one that requires refrigeration, i.e., one that would otherwise degrade if stored at room temperature for extended periods of time. As used herein, an active agent is "in need of refrigeration" such that, if the active agent in the relevant formulation degrades, less than 90% of the active agent remains (e.g., as measured by HPLC) when the active ingredient (in the formulation, if appropriate) is stored at 25° C. for a period of 18 months. Examples include active agents that are down to 90% or less of their original levels when stored at 25° C. for less than 18 months, e.g., 12 months (e.g., 1-12 months), 6 months, or 3 months.

[0089] In one embodiment, the active agent degrades to less than 90% by weight of its original level when stored at room temperature (eg, 25° C.) for a period of 12 months.

[0090] Examples of active agents that may be delivered by the compositions of the present disclosure include, but are not limited to, antimicrobial agents, immunomodulatory agents, including immunostimulants and immunosuppressants, anti-cancer and / or anti-viral agents, e.g., nucleoside analogs, paclitaxel and its derivatives, anti-inflammatory drugs / agents, e.g., nonsteroidal anti-inflammatory drugs and corticosteroids, cardiovascular drugs, including cholesterol-lowering and blood pressure-lowering agents, analgesics, histamine H1, NK1 and 5-HT 3 Antiemetics including receptor antagonists, corticosteroids and cannabinoids, antipsychotics and antidepressants including serotonin uptake inhibitors, prostaglandins and derivatives, vaccines, and bone modifying agents. Diagnostic agents include radionuclide labeled compounds and contrast agents including X-ray, ultrasound and MRI contrast enhancing agents. Nutrients include vitamins, coenzymes, dietary supplements, and the like.

[0091] Instead, where a long duration of action is beneficial, particularly suitable active agents include those that normally have a short residence time in the body due to rapid degradation or excretion, and those that have poor oral bioavailability. These include peptide, protein and nucleic acid based active agents, hormones and other natural drugs in their natural or modified forms. By administering such agents in the form of a depot composition formed from the composition of the present disclosure, the agent is provided at sustained levels for a period that may extend to days, weeks or even months, despite having a fast clearance rate. This provides clear advantages in terms of stability and patient compliance with multiple daily dosing for the same period. In one embodiment, the active agent thus has a biological half-life (by entry into the bloodstream) of less than 1 day, e.g., less than 12 hours, e.g., less than 6 hours. In some cases, this may be as low as 1-3 hours or less. Suitable agents are also those that have poor oral bioavailability relative to that achieved by injection, where the active agent also or alternatively has a bioavailability of less than 20%, e.g., less than 2%, e.g., less than 0.2%, or less than 0.1%, in an orally administered composition. Suitable active agents according to the present disclosure are those that benefit from low temperature storage, e.g., refrigeration. Storage at low temperatures improves the shelf life of preformulations that include the active agent. Preformulations of the present invention may thus include active agents that are "in need of refrigeration" (e.g., as described herein), may benefit from an extended shelf life (e.g., a shelf life of more than 18 months (e.g., 24 months to 5 years) or more than 2 years), or may contain at least one volatile component (e.g., a volatile solvent, e.g., ethanol). Such volatile components are more reliably retained in the preformulation during storage if the storage occurs at refrigeration temperatures.

[0092] Where technically feasible, the active agents disclosed herein can also be used in the form of their salts.When the "salt" of an active agent is referred to herein, this refers to a pharma-ceutically acceptable salt.Such salts are well known in the art and include, for example, chloride salts, acetate salts or pamoate salts of bases, or alkali metal salts, alkaline earth metal salts, amino salts or alkylamino salts of acids.

[0093] The amount of bioactive agent formulated with the composition of the present disclosure is determined by its functional dose and the period that the depot composition formed by administration achieves sustained release.Typically, the dose that is formulated for a particular drug is roughly equivalent to the normal daily dose multiplied by the number of days that the depot achieves release.Obviously, this amount needs to be adjusted to take into account the adverse effects of large doses at the beginning of treatment, so this is the maximum dose that is generally used.The exact amount that is appropriate in any case can be easily determined by appropriate experimentation.

[0094] In embodiments, compositions of the present disclosure may include one or more peptide active agents. The peptide active agent may include 5-90 or 5-60 natural and / or synthetic amino acids (each independently, D- or L-isomers), in particular 5-50 or 5-40 amino acids. In one embodiment, the active agent is a peptide active agent having 45 or fewer amino acid residues, e.g., 30 or fewer amino acid residues. In one embodiment, the peptide active agent is a cyclic and / or constrained peptide active agent. Cyclic peptide active agents may have a ring size of 5-80 amino acids, e.g., 6-80 or 8-45 or 10-35 amino acids.

[0095] Peptide and protein based active agents include adrenocorticotropic hormone (ACTH) and fragments thereof, angiotensin and its related peptides, antibodies and their fragments, antigens and their fragments, atrial natriuretic peptides, bioadhesive peptides, bradykinin and its related peptides, calcitonin peptides including calcitonin and amylin and their related peptides, vasoactive intestinal peptide (VIP) including growth hormone releasing hormone (GHRH), glucagon, and secretin, opioid peptides including proopiomelanocortin (POMC) peptides, enkephalin pentapeptides, prodynorphin peptides and related peptides, pancreatic polypeptide-related peptide-like neuropeptides (NPY), peptide YY (PYY), pancreatic polypeptide (PPY), cell surface receptor protein fragments, chemotactic peptides, cyclosporines, cytokines, dynorphins and their related peptides, endorphins and P-lydotropin fragments, enkephalins and their related proteins, enzyme inhibitors, immunostimulatory peptides, and the like. and polyamino acids, fibronectin fragments and their related peptides, gastrointestinal peptides, gonadotropin releasing hormone (GnRH) agonists and antagonists, glucagon-like peptides 1 and 2, growth hormone releasing peptides, immunostimulatory peptides, insulin and insulin-like growth factors, interleukins, luteinizing hormone releasing hormone (LHRH) and their related peptides (equivalent to GnRH agonists as described below), melanocortin receptor agonists and antagonists, melanocyte stimulating hormone and their related peptides, nuclear localization signal related peptides, neurotensin and their related peptides, neurotransmitter peptides, opioid peptides, oxytocin, vasopressin and their related peptides, parathyroid hormone and its fragments, protein kinases and their related peptides, somatostatin and their related peptides, substance P and its related peptides, transforming growth factor (TGF) and their related peptides, tumor necrosis factor fragments, toxins and toxoids and functional peptides, e.g.Anti-cancer peptides including angiostatin, blood pressure lowering peptides, anti-blood coagulation peptides, and anti-microbial peptides; proteins, such as immunoglobulins, angiogenin, bone morphogenetic proteins, chemokines, colony stimulating factors (CSFs), cytokines, growth factors, interferons (type I and type II), interleukins, leptin, leukemia inhibitory factor, stem cell factor, transforming growth factor, and tumor necrosis factor, including human and veterinary drugs. Interesting classes of bioactive agents suitable for the present disclosure include the glycoprotein hormone family (gonadotropins (LH, FSH, hCG), thyroid stimulating hormone (TSH); the proopiomelanocortin (POMC) family, adrenocorticotropic hormone (ACTH); posterior pituitary hormones including vasopressin and oxytocin, the growth hormone family including growth hormone (GH), the pancreatic polypeptide family including human chorionic mammary gland troponin (hCS), prolactin (PRL), PP, PYY and NPY; melanin-concentrating hormone (MCH); orexins; Peptide hormones including those of the gastrointestinal hormones and peptides, including GLP-1 and GIP; ghrelin and obestatin; adipose tissue hormones and cytokines, including leptin, adiponectin, and resistin; natriuretic hormones; parathyroid hormone (PTH); the calcitonin family with calcitonin and amylin; pancreatic hormones, including insulin, glucagon, and somatostatin. Any synthetic peptides designed to have a similar receptor affinity spectrum to the peptides described above are also well suited for the present disclosure.

[0096] A further significant advantage of the depot composition of the present disclosure is that the active agent is gradually released over an extended period of time without the need for repeated dosing. The composition is therefore highly suitable for situations where patient compliance is difficult and unreliable or where dosage levels are highly important (e.g., active ingredients with mood-altering effects, those active ingredients with narrow therapeutic windows, and those administered to children or people whose lifestyles are incompatible with a reliable dosing regimen), and for "lifestyle" active ingredients where the disadvantages of repeated dosing may outweigh the benefits of the active ingredient. Particular classes of active ingredients for which this embodiment provides particular advantages include contraceptives, contraceptive hormones, especially hormones used in children, including growth hormones, antiaddictive drugs, and drugs used in the treatment of populations with poor compliance, such as patients suffering from schizophrenia, Alzheimer's, or Parkinson's disease, antidepressants, and anticonvulsants.

[0097] Cationic peptides and proteins are particularly suitable in certain embodiments, in which the peptide or protein may be selected from the group consisting of octreotide, lanreotide, calcitonin, oxytocin, interferon-beta, interferon-gamma, interleukin 4, interleukin 5, interleukin 7, or interleukin 8. Other suitable cationic peptides or proteins are those that have an isoelectric point above pH 7, e.g., above pH 8.

[0098] In one embodiment, a polar active agent is included in the composition. Particularly suitable polar active agents include peptide and protein active ingredients, oligonucleotides, and small water-soluble active ingredients, including those listed above. Of particular interest in this embodiment are the peptides octreotide and other somatostatin-related peptides, interferon alpha and beta, glucagon-like peptide 1 and glucagon-like peptide 2 receptor agonists, leuprorelin and other GnRH agonists, abarelix and other GnRH antagonists, granisetron and ondansetron and other 5-HT 3 It is a receptor antagonist.

[0099] GnRH analogs form one particular class of active agents that can be included in the preformulations of the present disclosure. GnRH analogs include synthetic or semi-synthetic compounds that interact with gonadotropin releasing hormone receptors to induce the release of the pituitary hormones follicle stimulating hormone (FSH) and luteinizing hormone (LH) as biological responses. GnRH analogs include GnRH agonists and antagonists. Suitable GnRH analogs for use in the present disclosure include those disclosed in WO 2006 / 075125, the disclosure of which is incorporated herein by reference. Particularly suitable GnRH analogs include those disclosed in WO 2006 / 075125, section from page 1, line 33 to page 2, line 29.

[0100] Since GnRH is a peptide hormone, typical GnRH analogues are peptides, particularly of 12 or less amino acids. Typically, such peptides are structurally related to GnRH I, II and / or III and / or one or more of the known analogues, including those listed herein. The peptides may contain only amino acids selected from those 20 α-amino acids represented in the genetic code, or may alternatively contain their isomers and other natural and unnatural amino acids (generally α, β or γ amino acids) and their analogues and derivatives. Particularly suitable GnRH analogues are constrained peptides of 6 to 12 alpha-amino acids.

[0101] In one embodiment, the composition comprises a gonadotropin releasing hormone receptor agonist selected from the group consisting of leuprolide (also called leuprorelin), goserelin, histrelin, triptorelin, buserelin, deslorelin, and nafarelin. In one embodiment of the present disclosure, the pre-formulation comprises, consists essentially of, or consists of goserelin.

[0102] When present, the GnRH analogue is generally formulated as 0.02-12% by weight of the total composition (based on the amount of free base).Typical values ​​are 0.1-10%, such as 0.2-8%, such as 0.5-6%, such as 1-5%.

[0103] The dose of GnRH analogue suitable to be included in the composition, and therefore the volume of the composition to be used, will depend on the release rate (e.g. as controlled by the type of solvent and the amount used) and duration of release, as well as the desired therapeutic level, the activity of the particular drug, and the rate of clearance of the particular active ingredient selected. Typically, amounts of 0.1-500 mg per dose are suitable to achieve therapeutic levels for 7-180 days. In embodiments, the dose of GnRH analogue in the composition may be 1-200 mg. For compositions containing leuprolide or goserelin, the level is typically approximately 1-120 mg (e.g. for a duration of 30-180 days). A suitable amount of leuprolide is approximately 0.02-1 mg per day during injection for a depot designed for release over 30 days to 1 year, e.g. for a depot designed for release over 3-6 months. Obviously, the stability of the active ingredient and the linearity of the release rate mean that the loading versus duration does not have to be a linear relationship. A depot administered every 30 days may have, for example, 2-30 mg of GnRH analogue. A 90 day depot may have 6-90 mg of GnRH analogue, for example one of the GnRH analogues set forth herein.

[0104] Somatostatin and somatostatin analogs form another specific class of active agents that may be included in the compositions of the present disclosure. Somatostatin (growth hormone release inhibitor, SST) is a natural peptide hormone with a wide distribution in animals, acting as a neurotransmitter in the central nervous system and having diverse paracrine / autocrine regulatory effects on several tissues. Two biologically active products, SST-14 and SST-28, are known in higher species, the latter being a congener of SST-14 that is extended at the N-terminus. SST-14 is a 14-residue cyclic peptide hormone with a disulfide bridge that creates a type II β-turn in a key binding sequence.

[0105] Suitable somatostatins for use in the present disclosure include endogenous SST-14 and SST-18, as well as somatostatin analogs, such as those disclosed in WO 2008 / 152401. Since SST-14 is a peptide hormone, typically somatostatin receptor agonists are peptides, particularly of 14 or fewer amino acids. Typically, such peptides are structurally constrained, for example, by being cyclic and / or having at least one intramolecular bridge. Amides, esters or, particularly, disulfide bridges are highly suitable. In some embodiments, somatostatin analogs exhibit type 2 beta turns. Such turns are present in critical regions of somatostatin. The peptides may contain only amino acids selected from those 20 α-amino acids represented in the genetic code, or may contain their isomers and other natural and unnatural amino acids (generally α, β or γ, L- or D-amino acids) and their analogs and derivatives.

[0106] Particularly suitable somatostatin analogs for use in the compositions of the present disclosure include those disclosed in WO 2008 / 152401, section from page 20, line 24 to page 21, line 19. In some embodiments, the composition may include endogenous somatostatin or a somatostatin analog selected from the group consisting of SST-14, SST-28, octreotide, lanreotide, vapreotide, and pasireotide (also referred to as SOM230), and salts thereof. In some, the somatostatin or somatostatin analog is SST-14 or octreotide, and salts thereof.

[0107] When present, somatostatin receptor agonists are generally formulated as 0.1-12% by weight of the total composition (based on the amount of free base), typical values ​​being 0.1-10%, such as 0.5-9%, for example 1-8%, for example 1-7% or 2-6%.

[0108] The dose of somatostatin receptor agonist suitable to be included in the composition, and therefore the volume of the composition to be used, will depend on the release rate (e.g. as controlled by the type of solvent and the amount used) and duration of release, as well as the desired therapeutic level, activity and rate of clearance of the particular active ingredient selected. Typically, an amount of somatostatin analogue of 1-500 mg or 5-300 mg per dose is suitable to achieve therapeutic levels for 7-90 days. For octreotide, the level is typically approximately 10-180 mg (e.g. for a duration of 30-90 days). Typically, the amount of octreotide is approximately 0.2-3 mg per day between injections. Thus, a depot administered every 30 days will have 6-90 mg, or a 90-day depot will have 18-270 mg of octreotide.

[0109] For pasireotide, the dosage is typically in an amount of approximately 0.05-40 mg per week of depot duration, such as 0.1-20 mg per week of duration (e.g. 1-5 mg per week), for a duration of 1-24 weeks, such as a duration of 2-16 weeks, such as 3 weeks, 4 weeks, 8 weeks, 10 weeks or 12 weeks. In an alternative embodiment, the composition may be formulated for weekly (e.g. every 7 days ± 1 day) dosing. A total dose of 0.05-250 mg of pasireotide per dose is suitable to achieve therapeutic levels for 7-168 days. In some embodiments, the dose of pasireotide may be 0.1-200 mg, such as 0.2-150 mg, such as 0.1-100 mg, such as 20-160 mg. Obviously, the effect on stability and release rate of the active ingredient means that loading versus duration may not be a linear relationship. A depot administered every 30 days may have, for example, 0.2-20 mg of pasireotide, or a 90 day depot may have 30-60 mg of pasireotide.

[0110] In another embodiment, the pre-formulation includes an active agent that is not endogenous somatostatin or a somatostatin analogue, for example, the peptide active agent can be a peptide that does not interact as an agonist or antagonist at any of the SST(1)-SST(5) receptors, particularly the corresponding human receptors.

[0111] In this alternative embodiment, such pre-formulation does not contain somatostatin or somatostatin analogue active agents. That is, there are active agents that do not fall within the scope of somatostatin analogues described in the previous section. In particular, in this embodiment, the pre-formulation may contain an active agent that is not selected from endogenous somatostatin, SST-14, SST-28, octreotide, lanreotide, vapreotide or pasireotide or salts thereof. Furthermore, in this embodiment, endogenous somatostatin, SST-14, SST-28, octreotide, lanreotide, vapreotide or pasireotide may be completely excluded from the pre-formulation. In one embodiment, the pre-formulation is free of somatostatin, somatostatin receptor agonists and somatostatin analogues.

[0112] Other active agents that may be included in the pre-formulations of the present disclosure are: GnRH antagonists, e.g., cetrorelix, ganirelix, abarelix, degarelix; GLP-1 and its analogues, such as GLP-1(7-37), GLP-1(7-36)amide, liraglutide, semaglutide, exenatide, and lixisenatide (AVE0010); Glucagon-like peptide 2 agonists (GLP-2) and their analogues, such as GLP-2 and ersiglutide (ZP1846); DPPIV inhibitors; sodium / glucose cotransporter 2 (SGLT2) inhibitors Includes.

[0113] Other peptides suitable for the present disclosure include angiopeptin, angiotensin I, II, III, antileukinate, anti-inflammatory peptide 2, aprotinin, bradykinin, bombesin, calcitonin, calcitriol, cholecystokinin (CCK), colony stimulating factors, corticotropin releasing factor, C-peptide, DDAVP, dermorphin-derived tetrapeptide (TAPS), dynorphin, endorphin, endostatin, endothelin, endothelin-1, enkephalin, epidermal growth factor, erythropoietin, fibroblast growth factor, follicle stimulating hormone, follistatin, follitropin, galanin, galanin-like peptide, galectin-1, gastrin, gastrin releasing peptide, G-CSF, ghrelin, glial derived neurotrophic factor, GM-CSF, granulocyte colony stimulating factor, growth hormone, growth hormone releasing factor, hepatocyte growth ... factors, insulin, insulin-like growth factor-I and I, interferons, interleukins, leptin, leukemia inhibitory factor, melanocortin 1, 2, 3, 4, melanocyte stimulating hormone metastin, monocyte chemotactic protein-1 (MCP-1), morphiceptin, NEP1-40, neuropeptide Y, neuropeptide W, orexin-A and orexin-B, oxytocin, p21-Cip1 / WAF-1, TAT fusion protein, parathyroid hormone, pigment epithelium derived growth factor (PEDF), peptides, peptides, prorenin handle region, peptide YY(3-36), platelet activating factor, platelet derived growth factor, prorenin decapeptide, protegrin-1, PR39, prolactin, relaxin, secretin, substance P, tumor necrosis factor, urocortin, vascular endothelial growth factor, vasoactive intestinal peptide, and vasopressin.

[0114] The short elimination half-life of opioids, such as morphine, hydromorphone, and oxycodone, requires that these drugs be administered frequently to achieve round-the-clock analgesia, making them excellent candidates for long-acting release formulations.Fentanyl and buprenorphine undergo significant first-pass metabolism and lack sufficient bioavailability after oral administration.With their high potency, fentanyl and buprenorphine are excellent candidates for the long-acting injectable depot composition of the present disclosure.Sufentanil, remifentanil, oxymorphone, dimorphone, dihydroetorphine, diacetylmorphine are other strong opioid receptor agonists suitable for use in the present disclosure.

[0115] Buprenorphine is also used for the maintenance treatment of opioid addiction, and sometimes also cocaine and amphetamine and methamphetamine addiction, where current sublingual buprenorphine formulations suffer from low bioavailability, high variability and limited duration of effect, resulting in problems with unpredictable dose response and withdrawal symptoms, especially in the morning. These problems are effectively addressed by using the injectable depot composition of the present disclosure, as well as the problems of misuse and misdirection, where the need for high sublingual doses is utilized by injection, where the effect is considerably higher for the same dose, thus promoting drug misuse. Similarly, opioid antagonists can be used to treat addiction using the convenient injectable depot system as provided by the present disclosure. Suitable opiate antagonists for use with the present disclosure are naloxone, nalmefene, and naltrexone.

[0116] Antipsychotics including risperidone, iloperidone, paliperidone, olanzapine, asenapine, ziprazidone and aripiprazole are also highly suitable for the present disclosure, considering the possibility of improved treatment compliance by patients and by achieving stable plasma levels over time.Similarly, the present disclosure is useful in the treatment of dementia, Alzheimer's disease and Parkinson's disease, which adversely affect cognition.Suitable active ingredients include donepezil, rivastigmine, galantamine, and emantine, rasagiline and pramipexole.

[0117] Another group of active agents that may be included in the preformulations of the present disclosure are 5HT 3 It is an antagonist. 5HT 3 Antagonists are first and second generation 5HT 3 In one embodiment, the pre-formulation comprises a 5HT3 antagonist selected from the group consisting of ondansetron, tropisetron, granisetron, dolasetron, palonosetron, alosetron, cilansetron and / or ramosetron or mixtures thereof. 3The dose of antagonist, and therefore the volume of preformulation used, will depend on the release rate (e.g. as controlled by the type of solvent and the amount used) and duration of release, as well as the desired therapeutic level, the activity of the particular drug, and the rate of clearance of the particular active ingredient selected. Typically, amounts of 1-500 mg per dose are suitable to achieve therapeutic levels for 5-90 days. Such amounts may be 1-300 mg per dose. For granisetron, the levels are typically around 10-180 mg (e.g. for a duration of 3-60 days). Typically, the amount of granisetron is around 0.2-3 mg per day during injection for a depot designed for release over 30 days to 1 year, e.g. for a depot designed for release over 3-6 months. Obviously, the stability of the active ingredient and the linearity of the release rate mean that the loading versus duration does not have to be linear. A depot administered every 30 days may have, for example, 2-30 mg, or a 90 day depot having 6-90 mg of active ingredient.

[0118] In embodiments, the active agent is granisetron, buprenorphine, or a mixture of granisetron and buprenorphine, and salts thereof.

[0119] In an embodiment, the composition includes at least one active agent that is not a somatostatin receptor agonist. In this embodiment, the composition may be completely free of somatostatin receptor agonists. Thus, the composition may be free of active agents that interact as agonists or antagonists at any of the SST(1)-SST(5) receptors (particularly in humans).

[0120] Other optional components In one embodiment, the preformulation comprises at least 10 ppm EDTA. For example, suitable preformulations comprising an amine, such as ethanolamine, and EDTA are described in WO 2018 / 060212 (in particular pages 18-21), the entire disclosure of which is incorporated herein by reference. Suitable EDTA salts that allow for the presence of EDTA in the preformulation include tetrakis(ethanolammonium) EDTA or EDTA salts of ethanolamine, diethanolamine, meglumine, tris-hydroxymethylamine, ethylenediamine, and / or serinol.

[0121] Administration The preformulations of the present disclosure are generally formulated to be administered parenterally, for example, by subcutaneous injection. This administration is generally not an intravascular method, but may be subcutaneous (sc), intracavitary, or intramuscular (im). Typically, administration is by injection, a term used herein to indicate any method in which the formulation is passed through the skin, for example, by a needle, catheter, or needleless (without a needle) injector.

[0122] The preferred parenteral administration is by im or sc injection, most preferably by sc injection. An important feature of the composition of the present disclosure is that it can be administered by both im and sc as well as other routes without toxicity or significant local effects. It is also suitable for intracavitary administration. Deep sc injection has the advantage of being less deep and less painful for the subject than the (deep) im injections used for some current depots, and is technically the most appropriate in this case, as it combines ease of injection with low risk of local side effects. It is the inventors' surprising observation that the formulation achieves sustained release of the active agent over a predictable period of time by both subcutaneous and intramuscular injection. This therefore allows the site of injection to vary widely and allows the dose to be administered without close consideration of the tissue depth at the site of injection.

[0123] In one embodiment, applicable to all aspects of the present disclosure, the preformulations disclosed herein may be administered using an automatic injection device, e.g., an autoinjector, that typically includes a pre-filled glass syringe or glass cartridge (e.g., a glass syringe or cartridge) (provided that the interior surface is without a pre-applied silicone lubricant), a mechanical or electrical means for expelling the formulation (e.g., a spring or other resilient material under tension or compression, or an electric motor with a battery), a trigger or switch for initiating the injection, and a needle through which the injection is accomplished. Such an autoinjector filled with any of the formulations of the present disclosure clearly forms a further aspect.

[0124] The preferred lipid preformulations of the present disclosure provide non-lamellar liquid crystal depot compositions, particularly upon exposure to aqueous liquids in vivo.As used herein, the term "non-lamellar" is used to refer to normal or inverted liquid crystal phases (e.g., cubic or hexagonal) or L3 phase or any combination thereof.The term liquid crystal refers to any hexagonal liquid crystal phase, any cubic liquid crystal phase and / or any mixture thereof.Hexagonal, as used herein, refers to "normal" or "inverted" hexagonal (preferably inverted), unless otherwise specified, and "cubic" refers to any cubic liquid crystal phase. Although the skilled reader will have no difficulty in identifying those compositions with suitable phase behavior by reference to the descriptions and examples provided herein and WO 2005 / 117830, the most preferred compositional region for phase behavior is in the region of 40:60 to 70:30, preferably 45:55 to 55:45, more preferably 40:60 to 54:46, component i):phospholipid ratio. Ratios of approximately 50:50 (e.g., ±2) are highly preferred, and most preferred are approximately 50:50.

[0125] It is important to recognize that the preformulations of the present disclosure are of low viscosity (e.g., as discussed herein). As a result, these preformulations cannot be in a bulk liquid crystalline phase, since all liquid crystalline phases have a viscosity significantly higher than can be administered by a syringe or similar injection dispenser. The preformulations of the present disclosure therefore cannot be in a non-liquid crystalline state, e.g., solution, L 2 Or L 3 Phase, especially solution or L 2 It's inside. 2 The phase, as used throughout this specification, is preferably an "expanded" L-type glycerol containing more than 5% by weight, preferably more than 7% by weight, and most preferably more than 9% by weight of an organic monoalcohol solvent having a viscosity reducing effect. 2 L 2 The preformulations of the present disclosure in phase form one preferred set of preformulations, which generally contain at least 2% water as the polar solvent.

[0126] As used herein, the term "low viscosity mixture" is used to indicate a mixture that can be easily administered to a subject, particularly with a standard syringe and needle arrangement. This can be indicated, for example, by the ability to be dispensed through a small gauge needle from a 1 ml disposable syringe. Preferably, the low viscosity mixture can be dispensed by hand pressure through a 19 gauge needle, preferably a needle smaller than 19 gauge, for example, 22G (22 gauge), more preferably 23G (optionally even 25 gauge or 27 gauge or 29 gauge). In a particularly preferred embodiment, the low viscosity mixture should be a mixture that can pass through a standard sterile filtration membrane, for example, a 0.22 μm syringe filter. Typical ranges of suitable viscosities are, for example, 1-1000 mPas at 25° C. or other viscosities discussed herein. Suitable ranges of viscosities include 200-600 mPas at 25° C. or 300-500 mPas at 25° C. In embodiments applicable to all aspects of the present disclosure, thin wall (TW), extra thin wall (ETW) and ultra thin wall (UTW) needles are typically used. Suitable needles include 22G UTW and 23G TW.

[0127] It has been observed that by adding a small amount of low-viscosity organic monoalcohol solvent as shown herein, a very significant change in viscosity can be achieved.For example, adding only 5% solvent to lipid mixture can reduce the viscosity by 100 times, and adding 10% can reduce the viscosity by up to 10,000 times.To achieve this non-linear synergistic effect in reducing viscosity, it is important that a solvent with a suitable low viscosity and suitable polarity is used.Such solvents include those described herein below.Preferred low-viscosity mixtures include molecular solutions that include a dispersion of peptide active agent in molecular solutions of other components.

[0128] Upon administration, the preferred lipid-based preformulations of the present disclosure undergo a phase structure transition from a low viscosity mixture to a high viscosity (generally tissue-adhesive) depot composition. Generally, this occurs as a mixture of molecules, swollen L 2 and / or L 3 The transition from the liquid crystal phase to one or more (high viscosity) liquid crystal phases, such as normal or inverted hexagonal or cubic liquid crystal phases or mixtures thereof. Further phase transitions may also occur following administration. Obviously, a complete phase transition is not necessary for the present disclosure to function, but at least the surface layer of the administered mixture will form a liquid crystalline structure. In general, this transition is rapid for at least the surface area of ​​the administered formulation (that part that is in direct contact with air, body surface and / or body fluids). This most preferably lasts for a few seconds or minutes (e.g., 1 second to 30 minutes, preferably up to 10 minutes, more preferably 5 minutes or less). The remainder of the composition may phase change to a liquid crystal phase more slowly by diffusion and / or as the surface area disperses.

[0129] Without being bound by theory, it is believed that upon exposure to excess aqueous liquid, the pre-formulations of the present disclosure lose some or all of the organic solvent contained therein (e.g., by diffusion) and take up aqueous liquid from the body environment (e.g., the in vivo environment). For lipid pre-formulations, at least a portion of the formulation preferably produces a non-lamellar, particularly liquid crystalline phase structure. In most cases, these non-lamellar structures are highly viscous and do not easily dissolve or disperse into the in vivo environment. The result is a monolithic "depot" that occurs in vivo with only limited areas exposed to body fluids. Furthermore, because the non-lamellar structure has large polar, apolar and boundary regions, the lipid depot is highly effective in solubilizing and stabilizing active agents, such as peptides, and protecting them from degradation mechanisms. As the depot composition formed from the pre-formulation slowly degrades over days, weeks or months, the active agent is gradually released and / or diffuses out of the composition. Because the environment within the depot composition is relatively protective, the pre-formulations of the present disclosure are highly suitable for active agents that have relatively short biological half-lives (see above).

[0130] It is believed that by incorporating at least 10% polar solvent (particularly at least 5% water) in the preformulation, the rate of phase transition to a non-lamellar (e.g., liquid crystalline) phase at the surface of the injected preformulation can be enhanced compared to compositions containing organic solvents in the substantial absence of water. The performance of the resulting depot is thus improved and further control over the release of the active agent is achieved.

[0131] The depot system formed by the formulations of the present disclosure is highly effective in protecting the active agent from degradation, thus allowing for a sustained release period. Thus, the formulations of the present disclosure may provide an in vivo depot of the peptide active agent that requires administration only once every 5-90 days, preferably 5-60 days, more preferably 6-32 days. Obviously, a longer stable release period is desirable for patient comfort and compliance, and requires less time from the medical practitioner if the composition is not self-administered. If the composition is self-administered, patient compliance may be aided by weekly (e.g., every 7 days, optionally ±1 day) or monthly (e.g., every 28 or 30 days, optionally ±7 days) administration, so that there is no need to forget to administer.

[0132] A significant advantage of the depot precursors of the present disclosure is that they are stable homogeneous phases, i.e., they can be stored at room or refrigerator temperature for a significant period of time (preferably at least 6 months) without phase separation. As well as providing advantageous storage and easy administration, this allows the dose of peptide active agent (e.g., somatostatin analogue, e.g., octreotide) to be selected by reference to the species, age, sex, weight, and / or health condition of the individual subject by injecting a selected volume.

[0133] Thus, the present disclosure provides methods that include selecting a dosage that is specific to an individual, particularly depending on the subject's body weight. A means for this dose selection is the selection of the administration volume.

[0134] The preformulations of the present disclosure are highly advantageous in that they are stable for long-term storage in their final "ready to administer" form. As a result, they can be easily provided for administration by medical personnel, or by patients or their caregivers who do not have to be fully trained medical personnel and may not have the experience or skill to make complex preparations. This is particularly important in long-term, slow-effecting diseases, such as diabetes.

[0135] The amount of lipid component in a lipid-based pre-formulation is typically at least 40% by weight (eg, 40-95% by weight, such as 50-90% by weight or 50-80% by weight) of the total formulation.

[0136] As used herein, the terms "long-lived precipitate" and "visible precipitate" are used to refer to insoluble precipitates (e.g., particles) in a preformulation (e.g., a lipid-based preformulation in a glass syringe or glass cartridge) that do not redissolve when the preformulation is equilibrated at room temperature (15-25°C, e.g., 25°C) for a period of at least 15 minutes, e.g., at least 30 minutes or at least 1 hour (e.g., 1-24 hours). The term "refrigerated conditions" is used to refer to a temperature of 0°C to 10°C, e.g., a temperature of 2°C to 8°C. Injectable formulations, e.g., parenteral formulations, e.g., lipid-based preformulations as described herein, face regulatory requirements and the presence of particles / precipitates in formulations for parenteral (e.g., subcutaneous) administration is regulated by government agencies. The glass syringes or glass cartridges described herein containing the lipid-based preformulations are described as being (essentially) free of visible precipitates and / or turbidity (clear liquids), which is consistent with USP <790> Additionally, the containers (syringes or cartridges) as disclosed herein containing the lipid-based preformulations may be determined according to the USP <788> Contains no more than 6000 (NMT) particles 10 μm or larger (sediment and / or turbidity) and / or NMT 600 particles 25 μm or larger (sediment and / or turbidity) as determined by USP <788> According to the USP, particles are understood as "particulate matter in parenteral infusion solutions consists of mobile undissolved particles other than air bubbles that are unintentionally present in the solution"; i.e. <788> is suitable for detecting and quantifying precipitates and / or turbidity. <788> is a USP <790> or USP <790> It should be understood that the present invention may be used in conjunction with <788> (The European alternative to is European Pharmacopoeia 2.9.19.) Testing of containers may be carried out using Method 1 (light obscuration test) and if such containers are outside the specification range the test may be repeated using Method 2 (microscopic particle counting).

[0137] The terms "glass syringes or glass cartridges containing the lipid-based preformulations are essentially free of visible precipitate" and clear are used with the understanding that the preformulations are acceptable for parenteral, e.g., subcutaneous, injection in a subject.

[0138] Uses of diacylglycerol compositions In one aspect, the present disclosure provides use of a diacylglycerol composition having a fatty acid composition of at least 98% oleic acid (18:1) as determined according to European Pharmacopoeia 9.0, Method C, 2.4.22 (Composition of Fatty Acids by Gas Chromatography) in preventing or reducing the formation of long-lived precipitates in a pre-formulation comprising i) a diacylglycerol composition according to the first aspect of the disclosure, and ii) at least one biocompatible organic solvent.

[0139] In one embodiment, the use relates to use of a diacylglycerol composition, wherein the diacylglycerol composition according to the first aspect of the disclosure is the only diacylglycerol present in the pre-formulation, i.e. the pre-formulation is substantially free of diacylglycerol compositions other than the diacylglycerol composition according to the first aspect of the disclosure.

[0140] The biocompatible organic solvent component ii) is the same as component ii) of the pre-formulation according to the first aspect of the present disclosure. The biocompatible organic solvent component ii) in the use of the present disclosure may therefore be the same as any of the embodiments described with respect to the biocompatible organic solvent component ii) of the pre-formulation according to the aspect of the present disclosure.

[0141] In one embodiment, the use of the diacylglycerol composition of the present disclosure is in preventing or reducing the formation of long-lived precipitates in a pre-formulation when said pre-formulation is stored for a period of at least 24 hours, such as at least 1 month, such as at least 3 months, such as at least 6 months (e.g., 6 months to 3 years) at a temperature between 0° C. and 10° C., such as between 2° C. and 8° C. Such “cold storage” periods and conditions are applicable to all aspects, where the context permits.

[0142] As used herein, the terms "long-lived precipitate", "precipitate", "turbidity", "opalescence" are used to refer to a change in the preformulation, e.g., a precipitate that does not redissolve when the preformulation is equilibrated / reconditioned at room temperature (e.g., 25° C.) for a period of at least 1 hour (e.g., 1-24 hours) following cold storage. An alternative reconditioning method is to warm the prefilled syringe with the aid of body heat (e.g., by contact with the human body, e.g., by holding the syringe in the hand) for a sufficient time, e.g., 1-10 minutes, to recondition prior to administration, or any suitable method that does not have a negative effect on the active agent and / or lipid-based formulation. Reconditioning prior to administration (injection) also often involves turning the prefilled syringe containing the lipid-based composition described herein in the hand 5-50 times (e.g., approximately 10-20 times) through an arc of approximately 45-180°.

[0143] In another aspect, the present disclosure provides a method for preventing or reducing the formation of long-lived precipitate in a preformulation comprising: (i) a diacylglycerol composition; and (ii) at least one biocompatible organic solvent, when said preformulation is stored at a temperature between 0° C. and 10° C., e.g., between 2° C. and 8° C., for a period of at least 24 hours, e.g., at least 1 month, e.g., at least 3 months, e.g., at least 6 months (e.g., 6 months to 3 years); said method comprising forming said preformulation having a diacylglycerol composition according to the first aspect of the present disclosure. In particular, the described use is in a preformulation as described herein in combination with a glass syringe or glass cartridge without a silicone lubricant.

[0144] Pre-filled Glass Syringes In one aspect, the present disclosure provides a pre-filled glass syringe (as described in any embodiment herein) pre-filled with a lipid-based formulation, comprising a syringe barrel having an inner surface, the part of the inner surface of the syringe barrel that is always in contact with the lipid-based formulation is not pre-applied with silicone lubricant.The inventors have surprisingly established that when a pre-filled glass syringe pre-filled with a lipid-based formulation is prepared with the part of the inner surface of the syringe barrel that is always in contact with the lipid-based composition that is substantially not pre-applied with lubricant, the formation of long-lasting precipitate in the lipid-based formulation after storage under refrigerated conditions is prevented.An alternative to a pre-filled glass syringe is, for example, a pre-filled glass cartridge that is suitable for an autoinjector, for example, a pen.

[0145] As used herein, the term "lipid-based formulation" refers to any formulation that includes a lipid component. In one embodiment, the lipid-based formulation includes diacyl lipid. In one embodiment, the lipid-based formulation includes diacylglycerol with a fatty acid composition of at least 98% oleic acid (18:1) as determined according to European Pharmacopoeia 9.0, method C, 2.4.22 (composition of fatty acids by gas chromatography). In one embodiment, the lipid-based formulation forms or can form at least one liquid crystalline phase structure upon contact with excess aqueous liquid. In one embodiment, the lipid-based formulation is a preformulation according to the second aspect of the present disclosure (as described in any embodiment herein).

[0146] In one embodiment, the pre-filled glass syringe contains a lipid-based formulation comprising an active agent. In one embodiment, the active agent is one that requires refrigeration. In one embodiment, the active agent is a peptide active agent, e.g., a peptide active agent having 45 or fewer amino acid residues, e.g., 30 or fewer amino acid residues. In one embodiment, the active agent is a cyclic and / or constrained peptide active agent. In one embodiment, the active agent is a somatostatin or somatostatin analogue, e.g., a somatostatin or somatostatin analogue selected from the group consisting of SST-14, SST-28, octreotide, lanreotide, pasireotide, and vapreotide, or salts thereof. In one embodiment, the active agent is octreotide or a salt thereof, preferably octreotide chloride.

[0147] As used herein, a surface "substantially free" of any pre-applied lubricant refers to a surface that is covered to less than 1% by area (e.g., 1% or 0.000%), preferably less than 0.1% by area, and most preferably less than 0.01% by area, of any pre-applied lubricant.

[0148] In one embodiment, the portion of the interior surface of the syringe barrel that is in constant contact with the lipid-based formulation is substantially free of pre-applied silicone lubricant.

[0149] The pre-filled glass syringes of the present disclosure have a surprisingly low breakaway force. Breakaway force is the maximum amount of force required to initiate movement of the syringe plunger away from the syringe barrel. This represents the force required to overcome the static friction between the syringe plunger and the syringe barrel, and is therefore a measure of how easy it is to inject the composition.

[0150] In one embodiment the pre-filled glass syringe has a breakaway force of 35N or less, preferably 30N or less, preferably 25N or less, preferably 20N or less, preferably 15N or less, preferably 10N or less.

[0151] Without wishing to be bound by theory, it is believed that the lipid-based formulation provides sufficient lubrication, allowing the pre-filled syringe to be operated without excessive force, without the need for lubricants.

[0152] A "pre-applied lubricant" as referred to herein is any lubricant that is typically applied to glass syringes to allow for their smooth and tolerably low friction operation. Such lubricants are well known in the art. Examples may include petroleum-based lubricants or silicone lubricants.

[0153] Drug Products As described herein, there is a need for new treatment options using extended release (e.g., sustained release) drug products. One example of such a drug product is a glass syringe or glass cartridge containing a lipid-based pre-formulation, where at least the interior surface of the glass syringe is in contact with the lipid-based pre-formulation, the interior surface being free of a pre-applied silicone lubricant, and the lipid-based pre-formulation is a) 20-80% by weight of diacylglycerol having a fatty acid composition of at least 98% oleic acid (18:1) as determined according to European Pharmacopoeia 9.0, Method C, 2.4.22 (Composition of fatty acids by gas chromatography); b) 20-80% by weight of phospholipids; c) 1-30% by weight of a solvent; d) Bioactive agents (e.g., requiring storage at temperatures below 10° C.) Includes; wherein a) and b) are at least 94% by weight of the total lipid content of the lipid-based pre-formulation, and the lipid-based pre-formulation has a lipid content of at least 94% by weight of the lipid-based pre-formulation in accordance with USP 100001 after storage at a temperature of 10° C. or less, e.g., 0° C. to 10° C., e.g., 2° C. to 8° C., for at least one month, followed by equilibration at room temperature for a period of at least one hour. <790> and / or USP <788> The composition is a clear liquid (e.g., free of haze or turbidity) having a viscosity of less than 1000 mPas at 20° C. as determined in accordance with the method of the present invention and essentially free of visible precipitates.

[0154] When the different components, e.g., the glass syringe, preformulation, optional stopper described herein, are assembled into a drug product, i.e., a glass syringe or glass cartridge, containing the preformulation as described herein, low temperature storage, e.g., above freezing point and up to 10°C, is necessary or desirable to allow for long-term storage of the active agent, and therefore to achieve sufficient long-term stability, e.g., at least one year or more, that the individual components could not achieve separately. The complexity of the lipid-based preformulations disclosed herein, their interaction with glass surfaces, and especially the pre-applied silicone lubricant, injectability (e.g., injection force, withdrawal force, etc.), etc., required to achieve safe and efficient administration of lipid-based preformulations containing one or more active agents for extended release treatment, have proven challenging, especially in view of the need to provide a liquid preformulation (including active agent) without precipitation and without turbidity and / or opalescence. The glass syringes or glass cartridges and various aspects and embodiments disclosed herein have thus been combined to provide drug products suitable for refrigerated storage and to provide long-acting (e.g., long-term) lipid-based treatments that include active agents that require refrigeration.

[0155] LIST OF EMBODIMENTS E1) A diacylglycerol composition comprising at least 97.0% by weight, such as at least 97.5% by weight, such as at least 98.0% by weight, such as at least 98.5% by weight, of diacylglycerol having two fatty acid residues each independently having 16 to 20 carbon atoms and 1 or 2 carbon-carbon double bonds. E2) The diacylglycerol composition of E1, comprising less than 3% by weight of saturated fatty acid residues as measured by gas chromatography (GC). E3) The diacylglycerol composition according to E1, comprising less than 2% by weight, for example less than 1% by weight, of saturated fatty acid residues as measured by gas chromatography (GC). E4) The diacylglycerol composition according to E2 or E3, wherein the amount of saturated fatty acid residues in the composition is calculated according to European Pharmacopoeia 9.0, Method C, 2.4.22 (Composition of fatty acids by gas chromatography). E5) The diacylglycerol composition according to E1 to E4, wherein the diacylglycerol is a mixture of 1,2-diacylglycerol and 1,3-diacylglycerol. E6) The diacylglycerol composition according to E5, wherein the isomeric ratio of 1,2-diacylglycerol to 1,3-diacylglycerol is 5:1 to 1:5, for example, 4:1 to 1:4, for example, 1:1.5 to 1:3.5. E7) The diacylglycerol composition according to E1 to E6, wherein the diacylglycerol is glycerol dioleate. E8) The diacylglycerol composition according to E1 to E7, comprising 2 wt % or less, for example, 1.5 wt % or less, for example, 1 wt % or less, for example, 0.5 wt % or less of monoacylglycerol. E9) A diacylglycerol composition according to E1 to E8, comprising 2.5% by weight or less, for example, 2% by weight or less, for example, 1.5% by weight or less of triacylglycerol. E10) A preliminary formulation, i) a diacylglycerol composition according to any one of the preceding claims; and ii) at least one biocompatible organic solvent; Includes; The preformulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an excess of aqueous liquid. E11) The pre-formulation of E10, wherein the diacylglycerol composition of any of E1-E9 is the only diacylglycerol in the pre-formulation. E12) The pre-formulation of E10 or E11, wherein the at least one biocompatible organic solvent is a biocompatible oxygen-containing organic solvent; for example, a solvent selected from the group consisting of ethanol, N-methylpyrrolidone (NMP), propylene glycol, benzyl alcohol, DMSO, and mixtures thereof. E13) The preliminary formulation according to any one of E10 to E12, further comprising at least one type of phospholipid. E14) The pre-formulation of E13, wherein the at least one phospholipid is selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), and mixtures thereof. E15) The pre-formulation of E13 or E14, wherein the at least one phospholipid comprises or consists of a phosphatidylcholine. E16) A preliminary formulation according to any one of E13 to E15, wherein the ratio of diacylglycerol to phospholipid is in the range of 20:80 to 80:20, for example, 60:40 to 40:60. E17) The pre-formulation of any one of E10 to E16, further comprising a biologically active agent. E18) The preformulation of E17, wherein the biologically active agent requires refrigeration or the biologically active agent requires refrigeration. E19) The pre-formulation of E17 or E18, wherein the biologically active agent is a peptide active agent, e.g., a peptide active agent having 45 or fewer amino acid residues, e.g., 30 or fewer amino acid residues. E20) The pre-formulation of E19, wherein the peptide active agent is a cyclic and / or constrained peptide active agent. E21) The pre-formulation of any one of E17 to E20, wherein the biologically active agent is a somatostatin or somatostatin analogue, e.g., a somatostatin or somatostatin analogue selected from the group consisting of SST-14, SST-28, octreotide, lanreotide, pasireotide, and vapreotide, or a salt thereof. E22) The preformulation of E17-E20, wherein the biologically active agent is octreotide. E23) The preformulation of E17-E20, wherein the biologically active agent is SST-14. E24) The pre-formulation of E10-E23, further comprising an alkyl ammonium salt of EDTA. E25) (i) a diacylglycerol composition according to any one of E1 to E9, and (ii) at least one biocompatible organic solvent; Use of a diacylglycerol composition according to any of E1 to E9 in preventing or reducing the formation of long-lived precipitates in a preformulation comprising: E26) The use of E23, wherein the pre-formulation is substantially free of any diacylglycerol composition other than the diacylglycerol composition described in any of E1-E9. E27) Use according to E25 or E26 for preventing or reducing the formation of a long-lived precipitate in a pre-formulation when said pre-formulation is stored at a temperature between 0°C and 10°C, for example between 2°C and 8°C, for a period of at least 24 hours, for example at least 1 month, for example at least 3 months, for example at least 6 months. E28) The use according to E25-E27, wherein the long-lived precipitate does not redissolve when the preformulation is equilibrated at room temperature for a period of 1 hour. E29) When the preformulation is stored at a temperature between 0°C and 10°C, for example between 2°C and 8°C, for a period of at least 24 hours, for example at least 1 month, for example at least 3 months, for example at least 6 months, (i) a diacylglycerol composition; and (ii) at least one biocompatible organic solvent; 11. A method for preventing or reducing the formation of a long-lived precipitate in said preformulation comprising: forming said preformulation with a diacylglycerol composition according to any of E1-E9. E30) The method of E29, wherein the pre-formulation is formed with a diacylglycerol composition according to any of E1-E9 as the only diacylglycerol in the pre-formulation. E31) The method of E29 or E30, wherein the long-lived precipitate does not redissolve when the preformulation is equilibrated at room temperature for a period of 1 hour. E32) A pre-filled container comprising a glass cylinder and a stopper, a volume being defined by a space bounded by the glass cylinder and the stopper, said volume being at least partially filled with a pre-formulation as described in E10-E24. E33) A pre-filled container according to E32, which is a pre-filled syringe or a pre-filled cartridge. E34) A pre-filled glass syringe pre-filled with a lipid-based formulation comprising a syringe barrel having an interior surface, wherein a portion of the interior surface of the syringe barrel that is in constant contact with the lipid-based formulation is substantially free of pre-applied lubricant. E35) The pre-filled glass syringe of E34, wherein the portion of the interior surface of the syringe barrel that is in constant contact with the lipid-based formulation prior to use is substantially free of pre-applied silicone lubricant. E36) A pre-filled glass syringe according to E34 or E35, wherein the lipid-based formulation forms or is capable of forming at least one liquid crystalline phase structure upon contact with an excess of aqueous liquid. E37) The pre-filled glass syringe of any one of E34-E36, wherein the lipid-based formulation comprises a diacyl lipid. E38) The pre-filled glass syringe of any one of E34-E37, wherein the lipid-based formulation comprises diacylglycerol. E39) The pre-filled glass syringe of any one of E34-E39, wherein the lipid-based formulation comprises a diacylglycerol composition of any one of E1-E9. E40) The pre-filled glass syringe of any one of E34-E40, wherein the lipid-based formulation further comprises a bioactive agent. E41) The pre-filled glass syringe of E40, wherein the bioactive agent requires refrigeration. E42) The pre-filled glass syringe of E40 or E41, wherein the biologically active agent is a peptide active agent, e.g., a peptide active agent having 45 or fewer amino acid residues, e.g., 30 or fewer amino acid residues. E43) The pre-filled glass syringe of E42, wherein the peptide active agent is a cyclic and / or constrained peptide active agent. E44) A pre-filled glass syringe according to E40-E43, wherein the bioactive agent is a somatostatin or somatostatin analogue, e.g., a somatostatin or somatostatin analogue selected from the group consisting of SST-14, SST-28, octreotide, lanreotide, pasireotide, and vapreotide, or salts thereof. E45) A pre-filled glass syringe according to E40-E44, wherein the bioactive agent is octreotide or a salt thereof, preferably octreotide chloride. E46) A pre-filled glass syringe according to any one of E40-E45, wherein the lipid-based formulation is a pre-formulation according to any one of E10-E24. E47) A pre-filled glass syringe according to any one of E40 to E46, having a withdrawal force of 35N or less, e.g., 30N or less, 25N or less, 20N or less, 15N or less, 10N or less, or 5N or less. E48) A pre-filled glass syringe according to any one of E40 to E46, having a withdrawal force of 5 to 25 N. E49) A pre-filled glass syringe according to any one of E40 to E48, having a gliding force of 35N or less, e.g., 30N or less, 25N or less, 20N or less, 15N or less, 10N or less, or 5N or less. E50) A method of administering a pre-formulation as described in any of E10-E24 to a patient in need thereof, wherein the syringe containing the pre-formulation is maintained at 2-8°C for up to approximately 1 hour prior to administration and allowed to equilibrate at room temperature for approximately 1 hour prior to administration. E51) The method of E50, wherein the preformulation does not exhibit visible turbidity upon administration. E52) The method of E50 or E51, wherein the syringe is warmed at body temperature (e.g., by contact with the human body, e.g., by being held in the hand) for 1 to 10 minutes prior to administration. E53) The method of any of E49-E52, wherein the syringe is redirected in the hand 5-50 times (e.g., approximately 10-20 times) through an arc of approximately 45-180° prior to administration. E54) The method according to any of E49 to E53, wherein the syringe is a pre-filled glass syringe according to any of E34 to E48.

[0156] [Example] material All materials used in the examples were obtained from commercial sources and, where applicable, were of pharmacopoeial grade or the highest purity grade available. The following abbreviations are used throughout the examples: EtOH Ethanol (99.7%, European Pharmacopoeia) GDO Glycerol Dioleate (Cithrol GDO HP-SO-(LK) from Croda) OCT(Cl) Octreotide hydrochloride PG Propylene Glycol (European Pharmacopoeia) SPC Soy Phosphatidylcholine (Lipoid S100 from Lipoid)

[0157] General Procedure Preparation of 1,3-glycerol dioleate (1,3GDO)

[0158] [ka]

[0159] One equivalent of oleic acid (99% purity) was dissolved in dichloromethane and kept at about 23°C under an inert atmosphere (N2). The temperature was brought to 15°C and held at 15-20°C for 25 minutes, and 1.5 equivalents of oxalyl chloride were added dropwise. The mixture was stirred overnight under an inert atmosphere. The solvent and excess oxalyl chloride were removed and the remaining residue was added to a stirred inert (N2) dichloromethane suspension containing 0.45 equivalents of dimeric 1,3-dihydroxypropan-2-one, 0.5 equivalents of pyridine, and 0.25 equivalents of DMAP. The reaction mixture was kept at 20°C for 15 hours, after which the pyridine hydrochloride formed was removed by filtration and washed with dichloromethane. The combined organics were washed with 5% sodium chloride, 5% sodium carbonate, 0.1 M hydrochloric acid, and then again with 5% sodium chloride. The solution was dried and evaporated to give a semi-solid which was triturated using methanol and then refrigerated overnight. The collected solid was recrystallized from isopropyl ether and methanol to give 2-oxopropane-1,3-diyl dioleate (98.5% purity, HPLC).

[0160] The resulting 2-oxopropane-1,3-diyl dioleate was dissolved in 500 ml of tetrahydrofuran and 20 ml of water was added, followed by cooling to 5° C. and the dropwise addition of sodium borohydride, maintaining the temperature at approximately 5-10° C. The reaction was monitored by HPLC and after complete reaction, the addition of sodium borohydride was stopped, the solvent was removed and the residue was partitioned between ethyl acetate and water. The aqueous phase was retaken with ethyl acetate and the combined organics were dried over magnesium sulfate, filtered and concentrated. The residue was recrystallized twice from hexane to give 1,3-glycerol dioleate (98.5% purity by HPLC).

[0161] 1,3GDO isomerization The resulting 1,3-glycerol dioleate was converted to a mixture of 1,2- and 1,3-glycerol dioleate in the presence of a protic solvent by diluting the 1,3-glycerol dioleate with about 75% by volume of ethanol and heating the mixture to about 70° C. for 24 hours to reach a ratio (1,3-GDO / 1,2-GDO) of about 1.9. Optionally, the 1,3-glycerol dioleate was allowed to equilibrate in the presence of 50% ethanol at 40° C. for 4 days.

[0162] The resulting mixture of 1,2- and 1,3-glycerol dioleate had a purity of 98% and contained no more than 2% (area) (NMT) unsaturated fatty acids (sum of C18:2, C18:3 and C20:1) and NMT 1% (area) saturated fatty acids (sum of C16:0, C18:0 and C20:0) as determined according to Method C, 2.4.22. The composition of fatty acids by GC, European Pharmacopoeia 9.0 (presented as the peak area percentage of the corresponding methyl esters), i.e. the fatty acid composition contained at least 98% oleic acid (18:1).

[0163] Example 1: Storage stability of preformulations containing diacylglycerol compositions Lipid stocks were prepared by weighing soy phosphatidylcholine (SPC), a mixture of 1,2- and 1,3-glycerol dioleate (GDO) prepared as above, ethanol (EtOH) and propylene glycol (PG) and mixing by end-over-end until homogeneous. The final formulations were prepared by adding lipid stocks to weighed octreotide chloride (OCT(Cl)) powder, after which the vials were flushed with nitrogen and mixed by end-over-end until homogeneous. The formulations were then sterile filtered at 3 bar pressure, subsequently divided into vials and finally flushed with nitrogen. The pre-filled syringes were filled by adding approximately 0.5 g of the formulation to each syringe using a disposable pipette under ambient air and temperature conditions. Stoppers (e.g., commercial stoppers from BD or West) were placed with the aid of a metal wire and the plunger rod was used to place the stoppers in place, which was later removed. The bubbles (air) in the syringe are minimized as much as possible.The syringe is then placed in a climate chamber, and samples are taken at specific time points for visual inspection and HPLC analysis.All syringes, such as commercially available 1mL glass syringes, such as those sold by Gerresheimer, Schott and BD (Becton, Dickinson and Company), are pre-lubricated with silicone oil.Comparative compositions are prepared as above, except that GDO from a commercial source (Cithrol GDO HP-SO-(LK) from Croda) is used instead of the disclosed GDO prepared as above.

[0164] Additionally, samples (3-10) were prepared using a similar procedure but containing other additives and optionally excluding the active agent (octreotide chloride) and are included in Table 1.

[0165] [Table 1]

[0166] The samples were stored under refrigerated conditions at 2–8°C, 15°C, 25°C / 60% RH, and 40°C / 75% RH.

[0167] From samples 1-10, samples were removed at day 0, 1 month, 3 months, 6 months, 12 months, and 14 months. Samples from samples stored at 15°C, 25°C / 60% RH, and 40°C / 75% RH remained clean and homogenous throughout the study period. Samples from samples stored at 2-8°C were frequently frozen and inspected visually and under polarized light. Results from inspection of samples stored at refrigerated conditions are presented in Table 2.

[0168] [Table 2]

[0169] Examination of the refrigerated samples revealed that formulations prepared using regular GDO contained precipitate once thawed and / or the samples exhibited turbidity or opalescence. The precipitate appeared as grain-like crystals located near the stopper and glass wall.

[0170] Figure 1 shows a pre-filled syringe pre-filled with sample number 2 stored at 5°C for 14 months photographed in polarized light. Photographs were taken 0, 5, 15, and 30 minutes after removal from the climate chamber. Note that there were no white spots observed in the background in the formulation, and the formulation appeared completely clear within 15 minutes of equilibration at room temperature.

[0171] Analysis of other samples (3-10) stored at 2-8°C showed the presence of a precipitate, which generally (but not necessarily) redissolved within a few hours at room temperature, although in some samples the amount of precipitate, turbidity and / or opalescence remained. Some of the samples stored at 5°C and 15°C showed opalescence at 1 hour of testing with conditioning at room temperature. Opalescence was generally more evident in the comparative samples. Table 2 indicates "fail" when the sample contained precipitate or failed for other obvious reasons, e.g., excessive turbidity; opalescence was not considered a complete failure. Thus, Example 1 illustrates the use of a diacylglycerol having a fatty acid composition of at least 98% oleic acid (18:1), as determined according to European Pharmacopoeia 9.0, Method C, 2.4.22 (Composition of Fatty Acids by Gas Chromatography), that achieves a significant improvement upon storage under refrigerated conditions. Some samples were opalescent, motivating further investigation to provide a consistent lipid-based formulation useful for low temperature storage, e.g., 2-8°C.

[0172] HPLC analysis of samples from samples no. 1 and 2 revealed that the active agent was within specification for all samples, and decomposition of the active agent was slowed by refrigeration, indicating longer storage stability, as more than 90% of the original content remained.

[0173] Example 2 - Turbidity and Opalescence Studies Turbidity and / or opalescence appeared in some of the samples prepared in Example 1, and a preformulation identical to that in Example 1 stored in a glass vial under refrigerated conditions was reviewed, and it was surprisingly noted that the preformulation did not show opalescence upon visual inspection. Unlike the syringe, the glass vial was not accompanied by a pre-applied lubricant (silicone oil). Traditionally, glass syringes are treated with a lubricant, e.g., silicone oil, to allow acceptable injection force, e.g., to allow self-administration, and to ensure autoinjector compatibility (e.g., to allow for time of injection). Further investigations were conducted to develop an acceptable lipid-based formulation suitable for storage under refrigerated conditions.

[0174] The following preformulations without active agent were prepared as described in Example 1 and approximately 0.2 mL was loaded into a 1 mL glass syringe without pre-applied silicone oil. The syringe was sealed with a plunger, e.g., a suitable plunger commercially available from BD or West.

[0175] [Table 3]

[0176] The samples were visually evaluated as described in Example 1, e.g., samples 11-14 were stored at 2-8°C for 16 months and then visually inspected, and the results are presented in Table 4 and Figures 4 and 5.

[0177] [Table 4]

[0178] Samples 11 and 12 contained precipitate and were not acceptable, Sample 13 was already considered acceptable for administration at the first observation, while Sample 14 still showed opalescence throughout the evaluation.

[0179] Example 3 - Determination of the force required for injection. A typical injection device delivers forces up to approximately 20-25 N. Studies can be performed using appropriate samples to determine the appropriate configuration of formulation, needle, volume, injection mechanism and injection time. Methods based on ISO 11040 are suitable. Needle characterization will be in accordance with ISO 9626:2016.

[0180] A pre-filled syringe containing 1 ml of lipid controlled release formulation (containing placebo or active agent) without silicone lubricant (non-siliconized) is placed in a material tester with a load cell of 100 N. The plunger rod is attached without moving the (lubricated) plunger stopper to avoid compromising the "break-off force" measurement. After removing the needle cover, the test is run at a speed selected to achieve accurate dose delivery in a specific period of time. The load required is measured over time until the plunger stopper contacts the shoulder of the syringe barrel, at which point the test is stopped. The break-off force is determined using the maximum force on the force chart in the range of travel from 0 mm to ≦5 mm, and the sliding force is calculated from the average force between the end of the start-up period and just before the end of the plunger travel, instead the maximum force from just after the end of the start-up period to just before the end of the plunger travel is used to calculate the sliding force.

[0181] Testing of lipid controlled release formulations has revealed that such formulations adhere closely to the established Hagen-Poiseuille theory, in which injection time depends linearly on viscosity, needle length and fill volume; injection time depends on the fourth power of the syringe (barrel) inner diameter and is inversely proportional to the residual force and the fourth power of the needle inner diameter.

[0182] Since the formulations adhere well to the Hagen-Poiseuille theory, the average delivery force (gliding force) required for various viscosities, delivery times and needle diameters can be calculated and a model developed. An example based on the developed model is shown in the table below.

[0183] [Table 5]

[0184] The variation of injection time together with gliding force for various viscosities ranging from 100 to 1000 mPas is shown in Figure 2a (22G extra thin wall) and Figure 2b (23G thin wall).

[0185] The breakaway force was defined as the maximum force in the range of 0 mm to ≦5 mm of movement of the plunger stopper in the syringe barrel. The breakaway force for the pre-filled syringe described above containing 1 ml of lipid controlled release formulation, i.e., yielded a breakaway force that closely resembled the estimated sliding force as disclosed in FIG. 3 and was deemed suitable for use in self-administration or autoinjectors.

[0186] A comparative test was performed with a corresponding empty syringe lacking silicone lubricant. The test was stopped because the force of 45 N was insufficient to achieve the required breakaway and sliding force sufficient to inject into air (i.e., the syringe plunger did not move the required distance). Higher forces were not applied due to the risk of shattering the glass syringe. The breakaway force can be analyzed according to ISO11040-4:2015 (glass barrels for injectables).

[0187] A similar test was performed using a non-siliconized syringe with a barrel containing water with a 22G UTW needle and a non-lubricated stopper. A force of 45 N was reached without achieving a complete injection into air.

[0188] The test was repeated using a non-siliconized syringe barrel filled with water, using a 22G UTW needle and a silicone lubricated stopper. The results show that injection into air is possible with the non-siliconized barrel and silicone lubricated stopper, but requires a large force. Breakout forces of approximately 13N, 20N, and 18N (0.5, 1, and 5mm / sec plunger travel), respectively, were obtained, which are considered high considering the low viscosity of water.

[0189] Filling a non-lubricated syringe with the lipid composition disclosed herein met the requirements for break-off and gliding forces. Thus, it was found that a syringe filled with a lipid composition as disclosed herein without lubricating silicone oil and preferably sealed with a lubricated plunger stopper allows for extended storage at 2-8°C without visible precipitation and / or turbidity, e.g., opalescence, after reconditioning at room temperature. Furthermore, such pre-filled syringes did not require excessive injection force to inject a dedicated amount of lipid composition, e.g., 0.1-3 ml, over an acceptable period of time, e.g., 3-25 seconds, e.g., 5-20 seconds, e.g., 5-15 seconds. An example of the force required to allow the plunger to inject the formulation is 5-25 N, e.g., 8-20 n. The pre-filled syringes described herein fulfill the overall objective of enabling low temperature storage of syringes containing active agents that require such low temperature storage (e.g., 2-8° C.), while maintaining injectability and product compatibility (no precipitate and clear liquid) made possible by the aspects and embodiments described herein.

Claims

1. 1. A glass syringe or glass cartridge containing a lipid-based pre-formulation, wherein at least an interior surface of the glass syringe or glass cartridge is in contact with the lipid-based pre-formulation, the interior surface being free of a pre-applied silicone lubricant, the lipid-based pre-formulation comprising: a) 20-80% by weight of diacylglycerol having a fatty acid composition of at least 98% oleic acid (18:1) as determined according to European Pharmacopoeia 9.0, method C, 2.4.22 (Composition of fatty acids by gas chromatography); b) 20-80% by weight of phospholipids; c) 1-30% by weight of a solvent; d) Bioactive Agents Including; wherein a) and b) are at least 94% by weight of the total lipid content of said lipid-based pre-formulation, and said lipid-based pre-formulation is a clear liquid having a viscosity of less than 1000 mPas at 20°C, as determined according to USP <790>, after storage at a temperature of 10°C or less, e.g., 0°C to 10°C, e.g., 2°C to 8°C, for at least one month, followed by equilibration at room temperature for a period of at least one hour, and is essentially free of visible precipitate in a glass syringe or glass cartridge.

2. 13. A glass syringe or glass cartridge containing the lipid-based pre-formulation of claim 1, which contains or consists of no more than 6000 (NMT) particles of 10 μm or larger and / or NMT 600 particles of 25 μm or larger as determined by USP <788>.

3. 3. A glass syringe or glass cartridge containing the lipid-based pre-formulation of claim 1 or 2, wherein the diacylglycerol comprises 2% by weight or less, such as 1.5% by weight or less, such as 1% by weight or less, such as 0.5% by weight or less of monoacylglycerol.

4. 4. A glass syringe or glass cartridge containing the lipid-based pre-formulation according to any one of claims 1 to 3, wherein the pre-formulation comprises 5% by weight or less triacylglycerol, such as 4% by weight or less triacylglycerol, such as 3% by weight or less triacylglycerol.

5. 5. A glass syringe or glass cartridge containing the lipid-based pre-formulation according to any one of claims 1 to 4, wherein the phospholipid is phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), dioleylphosphatidylcholine and mixtures thereof.

6. A glass syringe or glass cartridge containing the lipid-based pre-formulation according to any one of claims 1 to 5, wherein the phospholipid is phosphatidylcholine (PC) or dioleylphosphatidylcholine.

7. 7. A glass syringe or glass cartridge containing the lipid-based pre-formulation according to any one of claims 1 to 6, wherein the ratio of diacylglycerol to phospholipid is in the range of 20:80 to 80:20, for example 60:40 to 40:

60.

8. 8. A glass syringe or glass cartridge containing the lipid-based pre-formulation according to any one of claims 1 to 7, wherein a) and b) are at least 95% by weight, such as at least 96% by weight, such as at least 97% by weight, of the total lipid content of the pre-formulation.

9. 9. A glass syringe or glass cartridge containing the lipid-based pre-formulation of any one of claims 1 to 8, wherein the solvent is selected from the group consisting of ethanol, propylene glycol (PG), water for injection (WFI), benzyl alcohol, dimethylsulfoxide (DMSO), and N-methyl-2-pyrrolidone (NMP) and mixtures thereof.

10. A glass syringe or glass cartridge containing the lipid-based pre-formulation according to any one of claims 1 to 9, wherein the solvent is ethanol or a mixture of ethanol and propylene glycol (PG).

11. 11. A glass syringe or glass cartridge containing the lipid-based pre-formulation according to any one of claims 1 to 10, wherein the biologically active agent is a drug requiring storage at a temperature below 10°C, for example between 0 and 10°C.

12. 12. A glass syringe or glass cartridge containing the lipid-based pre-formulation of any one of claims 1 to 11, wherein the bioactive agent is a peptide active agent, such as a peptide active agent having 45 or less, such as 30 or less amino acid residues.

13. A glass syringe or glass cartridge containing a lipid-based pre-formulation according to any one of claims 1 to 11, wherein the active agent is a cyclic and / or constrained peptide active agent.

14. 14. A glass syringe or glass cartridge containing a lipid-based pre-formulation according to any one of claims 1 to 13, wherein at least the interior surface of said glass syringe or glass cartridge is free of pre-applied lubricant.

15. A glass syringe or glass cartridge according to any one of claims 1 to 14, stored for at least 1 month, such as at least 3 months, such as at least 6 months, such as at least 12 months.

16. 16. The glass syringe or glass cartridge according to any one of claims 1 to 15, which is free of visible precipitate and / or turbidity after equilibration at room temperature for a period of 1 hour.

17. 17. A glass syringe or glass cartridge according to any one of claims 1 to 16, containing 0.1 to 3 ml, such as 0.2 to 2.5 ml, such as 0.4 to 1.5 ml of said lipid-based pre-formulation.

18. 18. A glass syringe or glass cartridge according to any one of claims 1 to 17, wherein the plunger sealing the syringe or cartridge has a breakaway force of 35N or less, such as 30N or less, 25N or less, 20N or less, 15N or less, 10N or less or 5N or less.

19. The glass syringe or glass cartridge according to any one of claims 1 to 17, wherein the plunger sealing the syringe or cartridge has a sliding force of 35N or less, for example, 30N or less, 25N or less, 20N or less, 15N or less, 10N or less, or 5N or less.

Citation Information

Patent Citations

  • glp-1 analog formulation

    JP2008542437A

  • Method for producing diacylglycerol

    JP2014169244A

  • Controlled-release peptide formulations

    JP2014520090A

  • Liquid depot formulations

    WO2005117830A1